Washington University in St. Louis

Washington University Open Scholarship
All Theses and Dissertations (ETDs)
January 2011

Skeletal Muscle Impairments in People with Diabetes and
Peripheral Neuropathy
Lori Tuttle
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/etd

Recommended Citation
Tuttle, Lori, "Skeletal Muscle Impairments in People with Diabetes and Peripheral Neuropathy" (2011). All
Theses and Dissertations (ETDs). 352.
https://openscholarship.wustl.edu/etd/352

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has
been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington
University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Interdisciplinary Program in Movement Science

Dissertation Examination Committee:
Michael Mueller, Chair
W. Todd Cade
Gammon Earhart
David Sinacore
Susan Stark
Michael Strube

SKELETAL MUSCLE IMPAIRMENTS IN PEOPLE WITH DIABETES AND
PERIPHERAL NEUROPATHY
by
Lori Jeanne Tuttle

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2011
Saint Louis, Missouri

copyright by
Lori Jeanne Tuttle
2011

Abstract of the Dissertation
Skeletal Muscle Impairments in People with Diabetes and Peripheral Neuropathy
by
Lori Jeanne Tuttle
Doctor of Philosophy in Movement Science
Washington University in St. Louis, 2011
Dr. Michael J. Mueller, Chairperson

Diabetes mellitus (DM) is a chronic disease that affects almost 24 million people
and has large socioeconomic costs. Of these 24 million people, 60-70 % will develop
some form of nervous system impairment, including peripheral neuropathy (PN). It is
important to understand muscle structure and impairments in people with DM+PN in
order to determine appropriate interventions to limit the disability that is associated with
DM+PN. The objectives of this research are to describe skeletal muscle structure in
people with DM+PN, to determine whether neuropathic muscle structure and
composition are associated with movement impairments and functional limitations, and
whether neuropathic muscle can be modulated by activity level and/or an exercise
intervention.
In Chapter 2, we examine whether intermuscular adipose tissue (IMAT) volumes
are different between groups with DM, DM+PN, and a group without DM or PN
(NoDMPN). We report that there is no difference in IMAT volumes in these groups, but
that increased IMAT is associated with poorer physical performance and the DM+PN
ii

group had the lowest measures of physical performance. In Chapter 3, we examine
whether activity level in people with DM+PN is associated with IMAT. We report that
activity level is inversely associated with IMAT volumes. In Chapter 4, we examine
whether an exercise intervention for people with DM+PN is able to improve function and
change IMAT and muscle volumes. We report that our duration-based exercise program
was successful in increasing 6 minute walk distance, but there was no change in IMAT or
muscle volumes. In Chapter 5, we provide a case report detailing an exercise
intervention for a specific individual with DM+PN who was able to increase his average
activity level and shows improvement in muscle performance and physical function.
Overall, our results suggest that people with DM+PN have lower levels of
physical performance than their peers and increased IMAT is associated with poor
physical performance. Increased activity levels are associated with decreased IMAT
volume. People with DM+PN are able to safely increase their walking distance following
an exercise intervention, but we did not see a change in muscle composition. Additional
research is needed to determine the specific roles of IMAT in skeletal muscle and
function.
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Chapter 1:
Background and Significance

1

Diabetes mellitus is a chronic disease that affects almost 24 million people
(diagnosed and undiagnosed), results in significant physical disability, and creates large
socio-economic costs.1 The effects of diabetes mellitus on body composition and muscle
structure and impairments may explain the impaired physical function associated with
diabetes mellitus. Peripheral neuropathy is a frequent complication of diabetes mellitus
and is associated with lower extremity sensory disturbances, muscle weakness, and
functional deficits. People with diabetes and peripheral neuropathy display an abnormal
infiltration of fat in the intra- and extra-cellular compartments of their lower extremity
musculature that is not noted in their peers.2,3, 4,5 The extent to which neuropathy in
particular contributes to this fatty infiltration is unknown. It is also unknown whether
fatty infiltration in the muscle contributes to muscle weakness and if so, whether the fat
infiltration and muscle weakness can be reversed or attenuated through exercise or other
interventions. Magnetic resonance imaging (MRI) has the potential to increase our
understanding of muscle composition and dysfunction and to help optimize rehabilitation
strategies. The mechanism for decreased physical function in people with diabetes is
important for physical therapists and other health care providers to understand so that the
optimal rehabilitation strategies for the recovery of muscle function can be determined in
order to reverse or prevent further disability. In this introductory chapter, I will briefly
overview muscle structure and impairments in DM and PN, the relationship of IMAT to
physical function, and the effect of exercise on IMAT.

Muscle Structure and Impairments in Diabetes and Peripheral Neuropathy
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The incidence and prevalence of diabetes mellitus and complications related to
diabetes mellitus are reaching epidemic levels.1 Comorbidities and conditions that are
often related to diabetes such as obesity,6,7 heart disease,6,7,8 stroke,7 and arthritis,7 have
been identified as contributors to disability in people with diabetes.9, 10 The effects of
diabetes mellitus on body composition (muscle adaptations in particular) as well as
muscle function are now being examined as contributors to the impaired physical
function that is associated with diabetes.9- 11
Sixty to 70 percent of individuals with diabetes mellitus have mild to severe
forms of nervous system disease.1 Individuals with diabetes and peripheral neuropathy
develop sensory loss as well as muscle weakness and motor dysfunction.12 Andersen et
al.13 reported strength losses of ~21% in the ankle musculature of individuals with
diabetes mellitus. The severity of peripheral neuropathy has been associated with muscle
weakness in type 1 and type 2 diabetes mellitus.14 In another study, Andersen et al.12
used magnetic resonance imaging (MRI) to demonstrate that muscle atrophy underlies
motor weakness of the distal extremities in individuals with diabetes mellitus and
peripheral neuropathy. However, the effect of diabetes mellitus and peripheral
neuropathy on muscle quality remains a topic of interest because most individuals with
diabetes mellitus do not display noticeable muscle atrophy despite muscle weakness
compared to individuals without diabetes mellitus. The Health, Aging, and Body
Composition study verified that arm and leg muscle mass do not accurately predict
muscle strength for older adults with diabetes mellitus.9 They studied 485 older adults
with diabetes mellitus that had larger arm and leg muscle mass than those persons
without diabetes and found that diabetes is associated with lower strength and muscle
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quality (defined as muscle strength per unit regional muscle mass, assessed by DXA),
and may contribute to the development of disability in older adults with diabetes
mellitus.9 Another Health, Aging, and Body Composition study was the first to report
data on how muscle mass and strength in people with diabetes mellitus change over
time.10 These data showed that individuals with diabetes mellitus experience a greater
loss of muscle strength and quality than people without diabetes mellitus.10 Despite the
high prevalence of diabetes and peripheral neuropathy and their potentially devastating
effects on strength and function, little is known about neuropathic skeletal muscles and
their impact on function or their ability to adapt to an exercise program.
Goodpaster et al.5 showed that accumulation of adipose tissue (measured by
computed tomography) within the fascia surrounding skeletal muscle in the thigh is
associated with insulin resistance. Goodpaster et al.2 performed a subsequent study to
examine whether skeletal muscle fat is characteristic of elderly individuals with diabetes,
hyperinsulinemia, and impaired glucose tolerance. Subcutaneous thigh fat was similar,
however intermuscular adipose tissue (IMAT) was higher in the people with diabetes and
impaired glucose tolerance.2 Intermuscular adipose tissue (IMAT) is defined as the
visible adipose tissue beneath muscle fascia and between muscle groups (Figure 1).15,16
IMAT has been linked to insulin resistance, and has been described as a unique adipose
tissue depot that is similar to visceral adipose tissue in its risks for metabolic
impairment.2,4,17 They concluded that people with increased amounts of IMAT may be at
increased risk for metabolic disease, including diabetes mellitus.2
Because adipose tissue is associated with metabolic impairments, decreased
muscle function, and diabetes, investigators pursued the use of MRI methods to quantify
4

the amount of lipid within the muscle.17, 18,19 MRI allows for non-invasive, quantitative,
and reliable measurements of quantifying IMAT.18 In addition, the inherent contrast
between different tissue types within the body when viewed via MRI make MRI an
excellent technique for morphometric measures of skeletal muscle.

Relationship of IMAT to physical function
In our previous work, we have shown that a group with obesity, diabetes, and
peripheral neuropathy had significantly greater amounts of IMAT in the calf compared to
a non-obese control group and that this IMAT was associated with poor physical
performance.11 It is unclear to what extent obesity contributes to this accumulation of
IMAT in skeletal muscle and to what extent the independent factors of diabetes and
peripheral neuropathy contribute to the amount of IMAT. In addition, the relationship
between IMAT and physical performance is not clear in these groups. Previous
investigators4,17 have shown that IMAT is linked to insulin resistance and that
denervation20 can also contribute to fat infiltration in muscle, but it is unclear whether
obesity alone accounts for a significant portion of IMAT infiltration.
It is also unknown whether IMAT accumulation is muscle or muscle
compartment specific, i.e. whether one muscle or a group of muscles tends to have more
IMAT than others. Different muscles in the calf have different amounts of fast twitch and
slow twitch fibers. For example, the gastrocnemius muscle is considered largely a fast
twitch muscle and is used more for large force production, while the soleus muscle is
considered more slow twitch and is a postural muscle that is better suited for using lipids
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as a fuel source.21 It is unknown whether different “types” of muscles are more affected
by IMAT infiltration in the presence of diabetes, diabetes and neuropathy, and obesity.
Increased physical activity has been shown to decrease pain and improve balance
in people with diabetes and peripheral neuropathy.22,23 Improved physical activity is
particularly important for people with diabetes, not only for improved glucose control
and cardiovascular fitness, but also because people with diabetes are two times more
likely to have limitations in physical mobility and this likelihood for physical mobility
limitations increases in the presence of peripheral neuropathy.23 The mechanisms for
physical mobility limitations in diabetes are unclear. IMAT has been linked to
immobilization in healthy young adults24 and has been shown to be reduced with exercise
in a population with diabetes and without peripheral neuropathy,25 indicating that
physical activity may be a potent modifier of IMAT content in skeletal muscle. IMAT
has also been shown to be higher in the affected limb in people with chronic stroke26 and
spinal cord injury.27 IMAT has been shown to be higher in rotator cuff injury with nerve
involvement20 indicating that nerve dysfunction (such as peripheral neuropathy) could
impact IMAT.

Effect of Exercise on IMAT
The benefits of exercise to help control diabetes mellitus and reduce subsequent
complications are well known and accepted.28,29 Besides improved diabetes control and
lower mortality rates, walking and increased activity appear to improve complications
from peripheral neuropathy.22 The evidence of the benefits of exercise for people with
diabetes has led the American Diabetes Association (ADA) and the American College of
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Sports Medicine (ACSM) to recommend that adults with diabetes participate in at least
30 minutes per day of moderate-intensity physical activity, but the effects of this exercise
program are untested in people with diabetes and peripheral neuropathy.30
IMAT in the thigh has been shown to reduce in size in response to increases in
activity and exercise programs in an older population31 as well as in a group with
diabetes, but no peripheral neuropathy,25 but it is unclear whether an exercise program
can impact IMAT in the calf in a population with diabetes and peripheral neuropathy.
Although people with diabetes and peripheral neuropathy clearly have lower extremity
impairments, little evidence exists to determine if these impairments can improve with
exercise. Studies investigating the effect of strengthening exercise have reported only
modest improvements32,33 and a Cochrane review of the literature concluded that there is
inadequate evidence to evaluate the effect of strengthening exercise for people with
diabetes and peripheral neuropathy.34
While there are a number of studies to support the beneficial effects of exercise in
people with diabetes, there is little information about how exercise will affect the muscle
of people with diabetes and peripheral neuropathy. Previous studies have demonstrated
that IMAT levels are increased in the presence of insulin resistance and diabetes, but it is
unclear whether this adipose tissue can adapt to exercise in the presence of diabetes and
peripheral neuropathy. A greater knowledge is needed to determine the muscular
impairments that exist in people with diabetes and peripheral neuropathy and whether or
not these impairments can be modified by an exercise intervention.

7

Mueller and Maluf35 have proposed a Physical Stress Theory for rehabilitation
speculating that essentially all biological tissues adapt to the stresses placed upon them,
provided the stresses are not above a threshold that would cause injury. Based on this
theory, neuropathic muscle and skin should be able to adapt to increased activity and an
exercise program. It is not clear what the appropriate magnitude and duration of activity
and exercise is necessary and safe to cause adaptation in neuropathic muscle and skin.

PRIMARY PURPOSE: The objectives of this research are to describe skeletal muscle
structure in people with diabetes and peripheral neuropathy, to determine whether
neuropathic muscle structure and composition are associated with movement
impairments and functional limitations, and whether neuropathic muscle can be
modulated by activity level and/or an exercise intervention.
SPECIFIC AIMS AND HYPOTHESES
Specific Aim 1: (Chapter 2)
To determine differences in muscle structure and composition (IMAT, muscle volume) in
specific calf muscles (gastrocnemius, soleus) and calf compartments (anterior, lateral,
deep) between people with diabetes and peripheral neuropathy (DM+PN), people with
diabetes and no peripheral neuropathy (DM), and people without diabetes and without
peripheral neuropathy (NoDMPN). Additionally, the relationship between calf muscle
structure and composition and measures of muscle performance (peak torque) and
physical function (PPT, 6 minute walk test, stair power) will be examined.
Hypothesis 1: People with DM+PN and people with DM will have greater
amounts of IMAT, and similar calf muscle volumes compared to the NoDMPN
8

group and the DM+PN group will display the largest amounts of IMAT of all 3
groups.
Hypothesis 2: The soleus muscle will display more IMAT than the gastrocnemius
muscle in people with DM+PN and people with DM.
Hypothesis 3: IMAT will be negatively correlated with peak torque and measures
of physical function.
Specific Aim 2: (Chapter 3)
To characterize activity levels (average daily step count) in people with DM+PN and to
determine relationships between activity level and IMAT volume in the calf, calf muscle
volume, muscle performance, physical function, and glucose control.
Hypothesis 1: People with DM+PN will take around 5,000 steps per day based on
prior observations and reports.
Hypothesis 2: Higher average daily step count will be associated with lower
IMAT volume, larger muscle volume, improved glucose control (lower HbA1c
levels), higher muscle performance, and higher physical function.
Specific Aim 3: (Chapters 4&5)
To determine the effect of a three month progressive exercise program on calf muscle
structure and composition (IMAT, muscle volume), muscle performance (peak torque),
and functional limitations (Physical Performance Test, 6 minute walk test) in people with
DM+PN who complete the 3 months of training (EX) and compare these outcomes to a
group of people with DM+PN who do not complete the training (CON).
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Hypothesis 1: The EX group will display decreased IMAT in calf muscles and
increased calf muscle volume after a progressive exercise program
compared to the CON group.
Hypothesis 2: The EX group will display increased dorsiflexor and plantarflexor
peak torque and improved measures of functional limitation after a progressive
exercise program compared to the CON group.

10

Figure 1. Panels A and C are cross sections of the calf via MRI. Notice that
subcutaneous adipose tissue and intermuscular adipose tissue are intact. Panels B and D
are the same cross sections with the subcutaneous adipose tissue removed leaving the
intermuscular adipose tissue and calf muscle. Panels A and B are images from a person
with diabetes and panels C and D are images from a person with diabetes and peripheral
neuropathy.

A.

B.

C.

D.
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Chapter 2

Intermuscular Adipose Tissue is Associated with Poor Functional Performance and
is Muscle Specific

This chapter is in review:
Tuttle LJ, Sinacore DR, Mueller MJ. Intermuscular Adipose Tissue is Associated with
Poor Functional Performance and is Muscle Specific. J Diabetes Complications.
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ABSTRACT
Purpose: People with obesity, diabetes, and peripheral neuropathy have high levels of
intermuscular adipose tissue (IMAT) volume which has been inversely related to physical
function. The primary purpose of this study was to determine if physical function and calf
IMAT are different between groups with diabetes mellitus (DM), DM and peripheral
neuropathy (DM+PN) and a group without DM or PN (NoDMPN).
Methods: We studied 45 people; 11 with type 2 diabetes, 24 with diabetes and peripheral
neuropathy, and 10 age and BMI matched people without diabetes and without peripheral
neuropathy and measured physical function (6 minute walk, Physical Performance Test,
stair power), muscle performance and muscle morphology (calf muscle volume, calf
IMAT).
Results: There were group differences for measures of physical performance: six minute
walk distance, physical performance test, and stair power (P<0.05). There were no
differences between groups in measures of calf muscle or calf IMAT volumes. Calf
IMAT infiltration was muscle and compartment specific. The gastrocnemius muscle had
a higher ratio of IMAT/Muscle volume than any other muscle or compartment
[0.286(0.37) (gastrocnemius) vs. 0.131(0.13) (soleus) vs. 0.154(0.16) (anterior
compartment)]. Calf IMAT was inversely related to physical performance on the 6
minute walk test (r=-0.47), and the physical performance test (r=-0.36). IMAT/Muscle
volume was inversely related to physical performance (PPT r=-0.44, 6MW r=-0.48, Stair
Power r= -0.30).
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Conclusions: Calf IMAT volume, diabetes and peripheral neuropathy are associated with
poor physical performance and calf IMAT may be muscle or compartment specific.
Key Words: physical performance, peripheral neuropathy, Intermuscular Adipose Tissue
(IMAT)
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Introduction
Previous research has shown that a group of people with obesity, diabetes, and
peripheral neuropathy had significantly greater amounts of intermuscular adipose tissue
(IMAT) in the calf compared to a non-obese control group and that this calf IMAT was
associated with poor physical performance (Hilton et al., 2008). IMAT is defined as the
visible adipose tissue beneath muscle fascia and between muscle groups (Lawler et al.,
2003 and Ruan et al. 2007). The unique contributions of obesity, diabetes, and diabetes
and peripheral neuropathy to the amount of IMAT in skeletal muscle are not clear. In
addition, the relationship between calf IMAT and physical performance is not clear in
these groups. IMAT in the thigh has been linked to insulin resistance, and has been
described as a unique adipose tissue depot that is similar to visceral adipose tissue in its
risks for metabolic impairment (Goodpaster et al., 2003, Goodpaster et al., 2000 and
Gallagher et al., 2005). Previous investigators (Goodpaster et al. 2000 and Gallagher et
al., 2005) have shown that IMAT is linked to insulin resistance and that denervation
(Rowshan et al., 2010) can also contribute to fat infiltration in muscle, but it is unclear
how the combination of diabetes, peripheral neuropathy and obesity impact IMAT
infiltration.
It is also unknown whether calf IMAT accumulation is muscle or muscle
compartment specific, i.e. whether one muscle or a group of muscles tends to have more
IMAT than others. Muscles in the calf have different distributions of fast twitch and slow
twitch fibers. For example, the gastrocnemius muscle is considered predominantly a fast
twitch muscle and is used more for large force production, while the soleus muscle is
considered more slow twitch and is a postural muscle that is better suited for using lipids
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as a fuel source (Edgerton et al., 1975). It is unknown whether muscles with different
“predominance” of fiber types are targeted by IMAT infiltration in the presence of
diabetes, diabetes and neuropathy, and obesity.
Therefore, the purposes of this study were a) to determine differences in physical
performance measures between people with diabetes mellitus (DM), people with diabetes
mellitus and peripheral neuropathy (DM+PN), and an age- and BMI- matched group
without diabetes and without peripheral neuropathy (NoDMPN); b) to determine the
relationship between calf muscle structure and composition, measures of muscle
performance (peak torque, average power) and physical performance (PPT, 6 minute
walk test, stair power); and c) to determine if the volume of IMAT present is different
between individual muscles and muscle compartments. We hypothesized that the groups
with DM and DM+PN would have greater volumes of IMAT in the calf, and similar calf
muscle volumes compared to the NoDMPN group, and that the DM+PN group would
display the largest volume of calf IMAT of all 3 groups. Additionally, we hypothesized
that calf IMAT volume would be inversely correlated with measures of physical
performance and that the soleus muscle would display more IMAT than the
gastrocnemius muscle and all other calf compartments across the three groups due to the
predominance of slow twitch fibers and higher lipid oxidation capacity in the soleus
muscle.
Methods and Procedures
Participants
Forty-five subjects participated in this study—11 people with type 2 diabetes
[5men/6 women; aged 56(9); BMI 35.5(6.4)], 24 people with diabetes and peripheral
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neuropathy [15 men/9 women; aged 64(13); BMI 32.6(6.3)], and 10 people without
diabetes and without peripheral neuropathy [4 men/6 women; aged 64(9); BMI
32.9(4.6)]. The groups were matched for age and BMI. Participants were recruited from
the Washington University School of Medicine Diabetes Clinic, Washington University’s
Volunteers for Health, the Center for Community Based Research, and from diabetes
clinics in the surrounding St. Louis community. This study is part of a larger study
investigating the effect of exercise for people with diabetes and peripheral neuropathy.
Participant characteristics are listed in Table 1. Participants were excluded if they
weighed more than 300 pounds (equipment weight limit), had a history of severe foot
deformity or amputation, any co-morbidity or medications that would interfere with
exercise (such as severe rheumatoid arthritis, peripheral arterial disease (absent pulses),
dialysis, or current cancer treatment). Participants provided written informed consent.
This study was approved by the Human Research Protection Office at Washington
University in St. Louis.
Assessments
Peripheral Neuropathy
Presence of peripheral neuropathy was determined based on an inability to feel
the 5.07 Semmes-Weinstein monofilament on at least one point on the plantar surface of
the foot, and on a vibration perception threshold greater than 25V as measured with a
biothesiometer applied to the plantar surface of the great toe (Maluf et al., 2003 and
Diamond et al., 1989).
Six Minute Walk Test
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All participants performed the six minute walk test (ATS Committee on
Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002) which was
validated previously in obese adults (Beriault et al., 2009). The participants walked back
and forth in a hallway between 2 cones that were placed 100 feet apart. The participants
were instructed that the goal was to walk as far as possible in 6 minutes. Six minute walk
distance was recorded as total distance walked (in feet).
Physical Performance Test (PPT)
The modified 9-item PPT was used to assess physical performance in all
participants. This test is designed to mimic activities of daily living and the 9-item PPT
has been shown to correlate well with disability and frailty (Brown et al., 2000, Binder et
al., 1999, and Brown et al., 2000). The 9-item PPT includes placing a book on a shelf,
putting a lab coat on and taking it off, picking up a coin from the floor, a 25 foot walk
down and back at a fast speed, turning in a 360 degree circle, simulated eating, writing a
sentence, climbing a flight of stairs with 10 steps, and sit to stand 5 times from a low
chair. Each of the items is scored on a scale of 0-4 based on the time it takes to complete
the task. Each task is performed twice and the average time is used to determine the 0-4
score. A maximum score is indicated by a score of 36.
Stair Power Measure
Stair power (in watts) was calculated based on the time it took each participant to
climb a flight of 10 stairs as part of the PPT (average of 2 trials) using the following
formula:
Stair Power = 3.171*Weight(kg)/time(sec) Climb avg*1/.1383*1/.7378
Where 3.171=Distance Traveled (m)
Climb avg= average time to climb a flight of 10 stairs (sec);
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1/.1383=Conversion (kgm/s to ftlbs/s);
1/.7378=Conversion (ftlbs/s to Watts)
Subjects were allowed to touch a handrail for balance, but not for pulling or pushing to
ascend the stairs.
Intermuscular Adipose Tissue (IMAT)
Calf intermuscular adipose tissue volumes were quantified using MRI on the right
leg of each participant. The MRI scans were performed with the participant in a supine
position with a Siemens CP extremity coil placed over the right calf muscle. The MRI
measurements were performed with a 3.0-Tessla superconducting magnet with a pulse
sequence of TE=12 milliseconds, TR=1,500 milliseconds, matrix=256x256; both a fat
saturated and a non fat saturated image were collected (Hilton et al., 2008). Thirty
transverse slices were collected beginning at the joint space of the knee and proceeding
distally. The slices were 7mm thick with no interslice gap. Nine consecutive slices were
selected to calculate muscle and IMAT volumes. Volumes were quantified using a PC
workstation and custom Matlab software. The software uses voxel brightness to
distinguish between muscle and adipose tissues. The subcutaneous adipose tissue was
removed from each image by drawing a line along the deep fascial plane surrounding the
calf muscle so that only the fat within and between the muscles (IMAT) was remaining.
The software uses edge detection algorithms to assist the user in separating the
subcutaneous fat from the muscle as well as separating individual muscles and muscle
compartments. In the calf, the muscle was divided into 1) the anterior compartment, 2)
the lateral compartment, 3) the deep compartment, 4) the gastrocnemius muscle, and 5)
the soleus muscle. Figure 1. Calf IMAT and calf muscle volumes are reported in cm3.
An additional variable, IMAT per muscle volume was also used in analysis. Based on
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test-retest reliability of 21 subjects, the error in measuring muscle volume is less than 1%
and less than 2% for measuring fat volumes on average in any muscle or compartment.
Ankle Dorsiflexion and Plantarflexion Peak Torque and Power
Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque and power
were assessed using a Biodex Multijoint System 3 Pro isokinetic dynamometer. The tests
were performed at angular velocities of 60○/s. The average power at 60○/s was
determined by the time-averaged integrated area under the curve at the constant velocity
of movement in the available range of motion (Hilton et al., 2008). All participants were
given 3 practice trials to ensure they were comfortable with the test. The mean values for
peak torque and average power were calculated for 3 trials.

Statistical Methods
Statistical analyses were performed using Systat for windows, version 13.0. An
analysis of variance was used to examine the main and interaction effects of group (DM,
DM+PN, NoDMPN) and measures of physical performance, calf muscle volume, and
calf IMAT (gastrocnemius, soleus, anterior compartment, lateral compartment, deep
compartment). Post-hoc t-tests were used to examine differences in groups (DM,
DM+PN, NoDMPN) on the variables of physical performance, calf IMAT, and calf
muscle volumes as needed based on the results of the ANOVA. Pearson correlations
were used to examine the associations between variables. Significance level was set at
P=0.05.

Results
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Group differences were significant for measures of physical performance: six
minute walk distance (P=0.04), physical performance test (P=0.001) and stair power
(P=0.04). Table 3. The NoDMPN group had a longer six minute walk distance than the
DM or DM+PN groups. The PPT scores were highest for the NoDMPN group and lowest
for the DM+PN group. Stair power values were highest for the NoDMPN group and
lowest for the DM+PN group. There were no group differences between total calf muscle
volume, calf IMAT volume, anterior compartment muscle volume, anterior compartment
IMAT volume, lateral compartment muscle volume, lateral compartment IMAT volume,
deep compartment muscle volume, deep compartment IMAT volume, soleus muscle
volume, soleus IMAT volume, gastrocnemius muscle volume, gastrocnemius IMAT
volume, and IMAT/Muscle Volume. Table 2. There were group differences in
dorsiflexor peak torque and power values with the DM group having higher dorsiflexor
peak torque and power than the DM+PN and NoDMPN groups (P=0.00), but no group
differences in plantarflexor peak torque and power (P=0.37).
Across all participants, calf IMAT volume was associated with BMI (r=0.31) and
IMAT volume was associated with poorer physical performance on the 6 minute walk
test (r=-0.47) and the physical performance test (r=-0.36). IMAT/Muscle Volume was
also associated with poor physical performance (PPT r=-0.44, 6MW r=-0.48). Muscle
volume was not strongly associated with 6 minute walk distance or physical performance
test score, but was associated with stair power (r= 0.51). Table 4.
The gastrocnemius muscle had a higher ratio of IMAT/Muscle volume than any
other muscle or compartment [0.286(0.37) (gastrocnemius) vs. 0.131(0.13) (soleus) vs.
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0.154(0.16) (anterior compartment) vs. 0.181 (deep) vs. 0.187 (lateral) P=.005] across all
participants.
Discussion
This study is the first to examine the impact of IMAT accumulation on specific
calf muscle compartments and muscle groups and relates it to calf muscle performance
and individual level physical performance. In addition, this study shows that people with
DM and DM+PN have lower physical performance in comparison to a group without DM
or PN matched for age and BMI. This study is the first to report that IMAT accumulation
may be muscle and compartment specific in people with diabetes, peripheral neuropathy,
or obesity.
Interestingly, while there were no measurable differences in muscle morphology
between the 3 groups, there was a difference in measures of physical performance
between the 3 groups. We found that the NoDMPN (obese) group had higher levels of
physical performance than the group with DM and the group with DM+PN. These
results could indicate that the pathologies of diabetes and diabetes and neuropathy have a
greater impact on physical performance than obesity alone.
Overall, the inverse correlation between calf IMAT volume and physical
performance indicates that IMAT accumulation is associated with physical performance
decline, but it appears that there are other factors, such as the presence of diabetes and/or
neuropathy that are key mediators of physical performance. The ratio of IMAT/Muscle
volume was inversely related to measures of muscle performance across all subjects. The
ratio of calf IMAT/Muscle volume may be a predictor of physical performance, but the
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IMAT/Muscle volume does not differ between those with diabetes and diabetes and
neuropathy compared to a NoDMPN, obese group of subjects. These results are
consistent with other reports in the literature and suggest measures other than absolute
muscle volume or muscle cross-sectional area are needed to completely characterize calf
muscle composition and muscle performance (Hilton et al., 2008, Park et al., 2006).
These data are also consistent with reports that people with DM or DM+PN have
limitations in physical performance and function beyond what is fully explained by
muscle changes alone (Park et al., 2006, Anderson et al., 1997). Certainly problems
secondary to sensory neuropathy can contribute to these deficits in physical performance
(Cavanagh et al., 1992).
We found, contrary to our expectations, that there were no group differences in
measures of IMAT volumes, or muscle volumes between groups with DM, a group with
DM+PN, and a NoDMPN group matched for age and BMI. These results indicate that
diabetes and peripheral neuropathy were not associated with IMAT accumulation in the
calf beyond their association with BMI in these groups of subjects. These results were
surprising because our previous study indicated that a group with diabetes, peripheral
neuropathy and obesity had two times the volume of IMAT compared to a non-obese,
non diabetic, non- neuropathic control group (Hilton et al., 2008). We expected that the
presence of diabetes or diabetes and neuropathy in addition to obesity would have an
additive effect on IMAT volume of the calf muscles. Our previous study had a small
sample size (6 in each group) and we reported IMAT volumes that were larger than what
we report here. Four of the six subjects with DM+PN in that group were sampled from a
patient sample with a history of foot ulcers rather than the community at large, so it is
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possible that we were capturing a group with more severe involvement of DM and PN
than what we report here.
This is the first study to report that the amount of IMAT/Muscle volume in the
calf was muscle specific in these pathologies. The gastrocnemius muscle had the largest
ratio of IMAT/Muscle volume of any of the calf muscles and compartments, which was
contrary to what we expected. It is possible that individual muscles are affected by
IMAT infiltration differently and the gastrocnemius muscle may be preferentially
affected by IMAT infiltration. We can only speculate that perhaps those muscles with a
predominance of fast-twitch fibers are affected by IMAT accumulation preferentially or
sequentially. The plantar flexor muscles are important for ankle stability, walking
velocity and cadence (Perry et al. 1993). Furthermore, the gastrocnemius is used more
for power and burst type activity compared to the soleus muscle which is most active for
postural control. Perhaps the gastrocnemius is more affected by IMAT than the soleus
muscle due to a greater reduction in power activities compared to postural activities in
these groups. Additional studies are required to determine the underlying mechanisms for
the IMAT accumulation in the gastrocnemius muscle and its propensity for having
greater fat infiltration than other calf muscles. Understanding the muscle specific
distribution of fat and the underlying mechanisms for fat infiltration may lead to
enhanced treatment strategies to improve the health of the muscle and individual. For
example, Marcus et al. (2008) demonstrated that people with type 2 diabetes were able to
improve performance, decrease fat, and increase lean tissue in the thigh muscles after a
16 week exercise program that included both aerobic and high-intensity eccentric
exercise training. Perhaps specific rehabilitation strategies that target the gastrocnemius
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muscle could alter the fat infiltration and improve deficits in muscle performance and
physical performance.
Of note, the NoDMPN group had an average HbA1c value of 5.8 which is
indicative of people at risk for developing diabetes (Zhang et al. 2010). This is consistent
with other reports in the literature that link IMAT with insulin resistance (Goodpaster et
al., 2000 and Gallagher et al., 2005) and this could be a potential indicator of those at risk
for developing diabetes. Interestingly, the NoDMPN group had higher levels of physical
performance than the DM or DM+PN groups, so perhaps an intervention targeted at
minimizing IMAT could diminish risk for developing diabetes and mitigate the
functional decline that is associated with diabetes and diabetes and peripheral neuropathy.
There are limitations that should be considered. First, we have a relatively small
sample size. Based on the small effect size between groups, a post-hoc power analysis
revealed that we would need to collect data on more than 3600 individuals to determine
group differences in total IMAT in the calf with a power of 0.80 and an alpha level at
0.05. Given this power analysis, we believe that total IMAT accumulation in the calf is
not due to an additive effect of diabetes and diabetes and neuropathy in this particular
sampling of subjects. The magnitude and impact of IMAT accumulation in specific calf
muscles or compartments in people with severe diabetes and peripheral neuropathy
requires additional investigation. This study is also limited in that we do not have a
measure of activity level for each participant, so it is possible that our groups could be
different from each other in levels of activity. Since the group with DM+PN was
originally recruited for an exercise study, it is possible that we have a selection bias
towards people with DM+PN who are higher functioning. In addition, this group only
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had 2 people with a history of plantar foot ulcer, so we do not believe these results are
generalizable to people with more severe complications and longer durations of diabetes
and peripheral neuropathy. Lastly, the correlations between the different variables within
and between groups only indicate association and cannot determine cause and effect.
In conclusion, this study found that increased calf IMAT was associated with
poorer physical performance and IMAT may target specific muscles and muscle
compartments differently, specifically; the gastrocnemius muscle was more affected than
other muscles of the calf. The groups with DM and DM+PN had lower measures of
physical performance than the NoDMPN group, suggesting that more severe impairment
in metabolic pathology along with IMAT accumulation impacts physical performance.
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Table 1. Subject Demographics by Group. Values are means(SD).
Diabetes Medication
(oral only/insulin
&oral)

HbA1c

DM Duration
(years)

226(33)

6/5

8.1(2.2)

8.1(6.9)

32.6(6.3)

217(45)

13/11

7.1(1.3)

12.9(9.0)

32.9(4.6)

213(41)

NA

5.8(0.2)

NA

Group

N

Gender
(M/F)

DM

11

5/6

56(9)

35.5(6.4)

DM+PN

24

15/9

64(13)

NoDMPN 10

4/6

64(9)

NA: Not Applicable

Age
(years)

BMI
(kg/m2)

Weight
(lbs)
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Table 2. ANOVA results: muscle morphology measures; all values are means(SD) in
cm3.
DM

DM+PN

No DMPN

P-Values

Muscle Volume

434(72)

407(88)

404(90)

0.65

IMAT Volume

65(36)

70(40)

67(54)

0.94

Anterior
Compartment
Muscle Volume

69(15)

65(14)

62(9)

0.57

Anterior
Compartment
IMAT Volume

10(11)

9(5)

7(5)

0.53

Lateral
Compartment
Muscle Volume

38(9)

37(11)

36(10)

0.85

Lateral
Compartment
IMAT Volume

5(3)

7(4)

6(5)

0.62

Deep
Compartment
Muscle Volume

54(13)

60(12)

51(15)

0.15

Deep
Compartment
IMAT Volume

8(4)

11(5)

9(6)

0.23

Soleus Muscle
Volume

130(26)

118(32)

127(28)

0.46

Soleus IMAT
Volume

14(8)

15(10)

14(14)

0.97

Gastrocnemius
Muscle Volume

142(27)

122(40)

128(31)

0.35

Gastrocnemius
IMAT Volume

27(15)

28(21)

31(28)

0.90

IMAT/Muscle
Volume

0.158(0.11)

0.193(0.16)

0.144(0.07)

0.58

Anterior Compartment: comprised of tibialis anterior, extensor digitorum longus, and
extensor hallucis longus muscles
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Lateral Compartment: comprised of peroneus longus and brevis muscles
Deep Compartment: comprised of the tibialis posterior, flexor digitorum longus and
flexor hallucis longus muscles
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Table 3. ANOVA results: physical performance measures. Values are means(SD)
DM

DM+PN

No DMPN

P-Values

DFPT (Nm)

15.3(7.5)a

4.5(5.3)

5.2(4.3)

0.00

DFPOW (W)

9.8(6.6)a

2.2(3.2)

2.3(2.4)

0.00

PFPT (Nm)

48.1(13.0)

51.4(16.5)

58.0(18.6)

0.37

PFPOW (W)

38.7(10.9)

41.9(18.1)

45.9(15.1)

0.38

6MW (feet)

1508(262)

1396(323)

1681(159)a

0.04

PPT

31(2.4)

28(4.0)

34(1.5)

0.001*

Stair Power (W)

671(163)

601(226)

808(327)

0.04*

* indicates all 3 groups are different
a

indicates that group is different from other 2 groups

DFPT=dorsiflexor peak torque
DFPOW=dorsiflexor power
PFPT=plantarflexor peak torque
PFPOW=plantarflexor power
6MW=six minute walk distance
PPT=physical performance test (9-item)
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Table 4. Correlation Matrix.

BMI

IMAT
vol

6MW

PPT

StairPOW

MuscleVol

IMAT/MusVol

0.31*

-0.18

0.01

0.21

0.49*

0.08

-0.47*

-0.36*

-0.18

-0.32*

0.93*

0.79*

0.58*

0.25

-0.48*

0.60*

0.24

-0.44*

0.51*

-0.30*

IMAT vol
6MW
PPT
Stair Pow
Muscle vol

-0.35*

* indicates significance (P<0.05)
IMAT=intermuscular adipose tissue volume
6MW=six minute walk distance
PPT=physical performance test (9-item)
Stair Pow=stair power
Muscle Vol=calf muscle volume
IMAT/MusVol=ratio of IMAT/Muscle Volume in the calf
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Figure 1. A) MRI image of calf with bone removed. B) Subcutaneous adipose tissue removed.
C) Calf divided into 5 compartments (anterior, lateral, deep, gastrocnemius, soleus)

A

B

C
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Chapter 3

Lower Physical Activity is Associated with Higher Intermuscular Adipose Tissue in
People with Type 2 Diabetes and Peripheral Neuropathy

Reprinted from Tuttle LJ, Sinacore DR, Cade WT, Mueller MJ, Lower Physical Activity
is Associated with Higher Intermuscular Adipose Tissue in People with Type 2 Diabetes
and Peripheral Neuropathy, Physical Therapy, in press, with permission of the American
Physical Therapy Association. This material is copyrighted, and any further reproduction
or distribution requires written permission from APTA. This paper is not in its final
edited form.
39

ABSTRACT
BACKGROUND. Increased lipid accumulation in skeletal muscle has been linked to
insulin resistance, impaired muscle performance, and impaired physical function. It is
unclear if physical activity is associated with lipid content in skeletal muscle, muscle
performance, or overall physical function.
OBJECTIVE. To characterize physical activity levels (average daily step count) in a
sample with diabetes and peripheral neuropathy and to determine the relationship
between step count, intermuscular adipose tissue volume (IMAT), muscle performance
(peak torque, power), and physical function.
DESIGN. 22 people with diabetes and peripheral neuropathy [15 men/7 women; aged
64.5(12.7); BMI 33.2(6.4)] participated. Average daily step count, HbA1c, modified 9item Physical Performance Test, 6 minute walk distance, calf intermuscular adipose
tissue volume (via MRI), and isokinetic dynamometry of the ankle muscles were
measured.
RESULTS. Average daily step count was 7754(4678) steps/day, with a range of 3088 to
20079 steps/day. There were 5 subjects with an average daily step count greater than
10,000. Average IMAT volume was 84(88)cm3. Greater average daily step count was
associated with younger age (r=-0.39, P<0.05) and with lower IMAT volume in the calf,
(-0.44, P<0.05). Lower IMAT volume was associated with greater muscle performance
(r=-0.45) and physical function (r=-0.43- -0.48).
CONCLUSIONS. Average daily step count was inversely related to IMAT and IMAT
was inversely related to muscle performance and overall physical function. In addition

40

we found that people with diabetes, peripheral neuropathy, and without severe foot
deformity appear to be able to take a high number of steps per day.
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Diabetes mellitus is a chronic disease that affects almost 24 million people, with
60-70% developing nervous system impairments, including peripheral neuropathy.1
Increased physical activity has been shown to decrease pain and improve balance
including in people with diabetes and peripheral neuropathy.2 Improved physical activity
is particularly important for people with diabetes, not only for improved glucose control
and cardiovascular fitness, but also because people with diabetes are two times more
likely to have limitations in physical mobility, particularly in the presence of peripheral
neuropathy.3 The mechanisms for physical mobility limitations in diabetes are unclear,
but previous work has demonstrated that people with diabetes, peripheral neuropathy and
obesity have an increased amount of adipose tissue (i.e. fat) in the muscles of the lower
extremity that is not noted in their peers and this increased intermuscular adipose tissue is
associated with poor physical functional status.4 Intermuscular adipose tissue (IMAT) is
defined as the visible extra-cellular adipose tissue that is located beneath the muscle
fascia and between and within muscle groups.5 The mechanism by which IMAT
potentially impairs physical function is unclear, but decreased muscle strength and power
has been associated with an increased amount of IMAT in the calf and thigh muscles of
people with diabetes and peripheral neuropathy thereby suggesting increased IMAT as a
mechanism for impaired physical function.4,6 IMAT has been linked to immobilization in
healthy young adults7 and has been shown to be reduced with exercise in a population
with diabetes and without peripheral neuropathy8 indicating that physical activity may be
a potent modifier of IMAT content in skeletal muscle. IMAT has also been shown to be
higher in the affected limb in people with chronic stroke9 and spinal cord injury10 and in
rotator cuff injury with nerve involvement11 indicating that nerve dysfunction (such as
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peripheral neuropathy) could impact IMAT. In addition, IMAT has been associated with
insulin resistance,12 suggesting that IMAT may contribute to or worsen the metabolic
impairments of skeletal muscle that accompany diabetes. It is therefore important to
determine if IMAT is influenced by physical activity, specifically walking activity and if
so, if increases in physical activity are associated with greater muscle performance,
glucose control and physical function in people with DM and PN.
The purpose of this study was to characterize activity levels (average daily step
count) in people with diabetes and peripheral neuropathy and to determine the
relationship between activity level and IMAT volume in the calf, calf muscle volume,
muscle performance, physical function, and glucose control. The American Diabetes
Association recommends that people take 10,000 steps per day,13 but we hypothesized
that people with diabetes and peripheral neuropathy would take around 5,000 steps per
day based on prior observations and reports.14-16 We hypothesized that higher average
daily step count would be associated with lower IMAT volume, larger muscle volume,
improved glucose control (lower HbA1c levels), higher muscle performance, and higher
physical function.
METHOD
Participants
Twenty-two subjects with type 2 diabetes and peripheral neuropathy [15 men/7
women; aged 64.5(12.7); BMI 33.2(6.4)] were recruited for this study as part of a larger
study involving exercise for people with diabetes and peripheral neuropathy from the
Washington University School of Medicine Diabetes Clinic and from diabetes clinics in
the surrounding St. Louis area. Participants were excluded if they weighed more than 300
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pounds (equipment weight limit), had a history of severe foot deformity or amputation,
any co-morbidity or medications that would interfere with exercise (such as severe
rheumatoid arthritis, peripheral arterial disease (absent pulses), dialysis, or current cancer
treatment). Participants were excluded if they had a current foot ulcer; 2 of the 22
participants had a history of a previous foot ulcer that had been healed for at least 6
months. Participants provided written informed consent. This study was approved by the
Human Research Protection Office at Washington University in St. Louis.
Assessments
Peripheral Neuropathy
Presence of peripheral neuropathy was determined based on an inability to feel
the 5.07 Semmes-Weinstein monofilament on at least one point on the plantar surface of
the foot and based on a vibration perception threshold of greater than 25 volts as
measured with a biothesiometer.16,17
Activity Monitoring
For the purposes of this study, activity level refers specifically to average daily
step count as recorded by a StepWatch activity monitor.* Participants were given an
activity monitor and were instructed to wear the monitor around their ankle during all
waking hours. The participants were given the monitor for at least 9 consecutive days
calculating an average of 7 days. The first and last days of wear were deleted because a
full 24 hours would not be recorded. For a day to be included, the monitor had to be
worn for at least 8 hours, and at least 1 weekend day was included in the 7 day average.
The device records strides per day and steps per day were calculated by multiplying

*

Orthocare Innovations, 840 Research Parkway, Suite 200,Oklahoma City, OK 73104.
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strides by 2 (1 stride equals 2 steps). Results of validity tests performed in our laboratory
indicate a mean absolute error of 1.1% (SD, 3.1%) for healthy obese subjects and 1.8%
(SD, 2.4%) for subjects with diabetes mellitus and peripheral neuropathy.16
Six Minute Walk Test
All participants performed the six minute walk test18 as a measure of physical
function and walking endurance which was validated previously in obese adults.19 The
participants walked back and forth in a hallway between 2 cones that were placed 100
feet apart. The participants were told that the goal was to walk as far as possible in 6
minutes; the test was not repeated. Six minute walk distance was recorded as total
distance walked in feet.
Physical Performance Test (PPT)
The modified 9-item PPT was used to assess physical function in all participants.
This test is designed to mimic activities of daily living and the 9-item PPT has been
shown to correlate well with disability and frailty.20-22 Each of the items is scored on a
scale of 0-4 based on the time it takes to complete the task. Each task is performed twice
and the average time is used to determine the 0-4 score. A maximum score is indicated
by a score of 36.
Intermuscular Adipose Tissue (IMAT)
Intermuscular adipose tissue volumes were quantified using MRI on the right leg
of each participant using previously established methods.4

The MRI scans were

performed with the participant in a supine position with a Siemens CP extremity coil
placed over the right calf muscle. The MRI measurements were performed with a 3.0-T
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superconducting MRI instrument† with a pulse sequence of TE=12 milliseconds,
TR=1,500 milliseconds, matrix=256x256. Thirty transverse slices were collected
beginning at the joint space of the knee and proceeding distally. The slices were 7mm
thick with no interslice gap with voxel size of 0.7x0.7x7mm. The fifteen center
consecutive slices were selected to calculate muscle and IMAT volumes. Volumes were
quantified using a PC workstation and Analyze Direct software version 9.0‡ which uses
voxel brightness to distinguish between muscle and adipose tissues.5 The subcutaneous
adipose tissue was removed from each image by drawing a line along the deep fascial
plane surrounding the calf muscle so that only the fat within and between the muscles
(IMAT) was remaining. On a subset of 10 participants, intraclass correlation coefficient
(2,1) values of the same scan by the same observer averaged 0.98 when scans were
measured at least 7 days apart.
Ankle Dorsiflexion and Plantarflexion Peak Torque and Power
Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque and power
as measures of muscle performance were assessed using a Biodex Multijoint System 3
Pro isokinetic dynamometer.§ The tests were performed at angular velocities of 60○/s.
The average power at 60○/s was determined by the time-averaged integrated area under
the curve at the constant velocity of movement in the available ankle joint range of
motion.4 All participants were given 3 practice trials to ensure they were comfortable

†

Siemens Corp, Citicorp Center, 153 E. 53rd St., New York, NY 10022.

‡‡

§

Mayo Clinic, 200 First St. SW, Rochester, MN 55905.

Biodex Medical Systems, 20 Ramsay Road, Shirley, NY 11967.
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with the test. The mean values for peak torque and average power were calculated for 3
trials.
Data Analysis
Statistical analyses were performed using Systat for windows, version 13.0. **
Pearson correlation coefficients were used to determine association between variables.
Multiple regression analysis was performed with average step count as the dependent
variable and IMAT volume, age, BMI, HbA1c, duration of diabetes, muscle performance
(dorsiflexion and plantarflexion peak torque and power) and physical performance (six
minute walk distance and physical performance test score) as the independent variables.
Statistical significance was set at P<0.05. Post hoc, the 22 participants were divided into
3 groups based on step count in an effort to determine if there was something different
between people who were taking more steps than the group mean (greater than 8000 steps
per day), those who were in our expected range of step count (5000-8000 steps per day),
and those who were below the expected step count (less than 5000 steps per day). A oneway ANOVA was performed with age as a covariate to determine differences in IMAT
volumes that were due to group differences in activity level. ANOVAs were also
performed to determine differences in IMAT volume, muscle volume, muscle
performance, PPT and 6 minute walk distance based on group differences in activity level
(Table 1). Statistical significance was set at P<0.05.

Results

**

Systat Software, Inc., 225 W Washington St., Suite 425, Chicago, IL 60606.
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Average daily step count in these 22 participants with diabetes and peripheral
neuropathy ranged from 3088 steps per day to 20079 steps per day with an average of
7754(4678) steps per day. Participant characteristics are listed in Table 1. In order to
characterize the people who were more active and those who were less active, the 22
participants were categorized into 3 groups based on average step count (less than 5000
steps/day, 5000-8000 steps/day, and greater than 8000 steps per day) (Table 1) . The
group that was taking less than 5000 steps/day had 3 times the volume of IMAT in their
calf muscles compared to the groups that were taking 5000-8000 steps per day and
greater than 8000 steps per day (157(127) cm3 vs. 53(27) cm3 vs. 42(22) cm3 ; P<0.05).
However, the more active group also was younger than the other 2 groups (Table 1)
therefore, a one-way ANCOVA also was performed with IMAT volume as the dependent
variable, step count as the independent variable and age as a covariate. Results were
unchanged and IMAT volumes remained significantly different (P=0.03) between the
groups.
A multiple regression analysis was used to determine the variance in average step
count accounted for by IMAT volume, age, BMI, HbA1c, diabetes duration, muscle
performance, and physical function (Table 2). IMAT accounted for 19% of the variance
in average step count (P=0.04). The other independent variables did not account for a
significant portion of the variance in IMAT in this sample (P>0.05).
Activity as indicated by average step count was associated with age (r=-0.39) and
with IMAT volume (r=-0.44), but average step count was not associated with glucose
control (as indicated by HbA1c), muscle performance, muscle volume, or physical
function (P>0.05) (Table 3). IMAT volume was associated with select indicators of
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muscle performance (plantarflexion peak torque r=-0.45, P=0.03) and physical function
(PPT r=-0.43 P=0.04; 6MW r=-0.48 P=0.02) in addition to an association with average
step count (r=-0.44 P=0.04).
Discussion
This study is the first to demonstrate an inverse relationship between physical
activity levels and intermuscular adipose tissue (IMAT) volume in calf muscle in people
with diabetes and peripheral neuropathy. We have also demonstrated a significant
relationship between increased IMAT volume and lower muscle performance and
physical function. This finding is in agreement with previous investigators who found
that increased IMAT was associated with lower muscle performance4,6,12 suggesting that
IMAT may be a potential pathway for intervention to attenuate the impairments
associated with diabetes and peripheral neuropathy.

However, these data provide only

an association between these variables and do not imply causation. More studies are
needed to elucidate the role of IMAT in these processes. In addition, these findings lead
us to question whether increasing physical activity could decrease IMAT volume and be
a way to improve physical function in people with DM and PN. IMAT has also been
linked to insulin resistance23-26 in people with metabolic syndrome as well as frank
diabetes. The exact relationship between IMAT and insulin resistance is not yet
understood, but there is some evidence that weight loss27 and exercise28-30 can decrease
the amount of IMAT and improve insulin sensitivity. It is unknown whether people with
diabetes and peripheral neuropathy demonstrate these same effects on IMAT in response
to exercise and weight loss.

49

We hypothesized that higher average daily step count would be associated with
less IMAT volume, larger muscle volume, improved glucose control, higher muscle
performance, and higher physical function. This study showed that average daily step
count is inversely correlated with IMAT volume, but step count was not correlated with
glycemic control, muscle volume, muscle performance or measures of physical function.
IMAT volume was inversely correlated with muscle performance (plantarflexor peak
torque) and with measures of physical function (PPT score and 6 minute walk distance).
These findings suggest that activity could be a modifiable factor that has the potential to
impact muscle morphology (IMAT volume) and therefore improve physical function. In
fact, the people who were the least active actually had three times the volume of IMAT in
the calf as the people who were most active, on average (Table 1). Physical activity has
been associated with IMAT in a young healthy population,7 but this is the first study
reporting that activity is associated with IMAT volume in a population with diabetes and
peripheral neuropathy. These results provide evidence for a potential way to impact not
only the metabolic disturbance of diabetes but to also improve the functional deficits that
have been shown to occur in people with diabetes and peripheral neuropathy. Indeed,
Marcus et al.8 demonstrated that people with type 2 diabetes were able to improve
performance, decrease fat, and increase lean tissue in the thigh after a 16 week exercise
program that included both aerobic and eccentric exercise training. Additional studies are
needed to determine if more intensive interventions targeted to increase activity or
muscle strength can improve muscle and physical function in people with diabetes and
peripheral neuropathy. While the relationship between average step count and IMAT
volume was significant, there was also great variability in IMAT volume, particularly in
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people with a lower step count. As noted in our multiple regression analysis, IMAT only
accounted for 19% of the variation in step count and there are many other factors that
could be contributing to the variability seen in both IMAT and step count. More studies
are needed to be able to determine the variety of factors that impact IMAT volume.
In our previous work4 we found that people with diabetes, peripheral neuropathy
and obesity had a greater amount of IMAT volume in their calf muscles than their agematched peers who did not have diabetes or peripheral neuropathy and who were not
obese. In our previous study, IMAT volume was related to muscle performance and
function. However, we did not have measures of activity level in our previous study. The
findings in this study that IMAT volume was associated with muscle performance and
function are consistent with our previous results and expand upon this previous work to
include activity level as a factor that may influence muscle performance and physical
function. The results suggest that activity is associated with muscle morphology and
could potentially be a way to improve the impaired physical function that accompanies
chronic diabetes.
Based on previous studies, we hypothesized that people with diabetes and
peripheral neuropathy would be taking around 5,000 steps per day.15,16 We hypothesized
this because generally, the expectation is that people with diabetes and peripheral
neuropathy are less active than their peers, however, the group for this study had an
average daily step count of 7919 and there were 5 people with diabetes and peripheral
neuropathy who were taking more than 10,000 steps per day. The average step counts in
this study are consistent with those from Maluf et al16; however they are significantly
higher than those reported by Armstrong et al.15 Because we were recruiting for an
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exercise study, our sample may be biased toward those who have high activity and
limited our ability to recruit participants who are less active.
Surprisingly, HbA1C levels were not associated with activity. This is in conflict
with other reports in the literature that indicate that exercise and increased physical
activity will improve glucose control.31 There are several potential explanations for this.
First, the participants in this study were not participating in a regular exercise program;
the activity measure is a measure of regular daily walking activity. Intensity of exercise
is a key factor in maintaining blood glucose control, and perhaps normal daily walking,
regardless of total number of steps, does not reach an intensity level that is consistent
with regulating blood glucose over the previous 3 to 4 month time period that HbA1c
indicates. Also, one limitation of this study is that we do not have any information on
diet in these participants and it is possible that dietary habits contributed more to overall
HbA1c values than low intensity physical activity in this particular sample. It is also
possible that some of the participants in this study were not compliant in taking their
daily medication, which could also adversely affect HbA1c values.
While this study provides important information about the role of activity in
people with diabetes and peripheral neuropathy, there are limitations that should be
considered. First, the participants in this study were all interested in participating in an
exercise study, so it is possible that our sample is biased towards those who tend to be
more active. It is unclear whether our results are generalizable to people who are taking
less than 3000 steps/day. In addition, we excluded people who had a current foot ulcer,
peripheral arterial disease, severe foot deformity or amputation, or who weighed greater
than 300 pounds. Our results should not be generalized to these populations. There is
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evidence that walking capacity and performance decrease in the presence of severe foot
deformity or amputation.32 Additional research is needed to clarify the contraindications
and safety precautions for a walking program or weight bearing exercise program given
various levels of foot deformities and impairments. Also, based on these data, we can
only say that step count and IMAT volumes are associated, but we cannot specify
causation.
In conclusion, physical activity is associated with IMAT volume and IMAT
volume is related to muscle performance and overall physical function. In addition we
found that people with diabetes, peripheral neuropathy, and without severe foot deformity
appear to be able to take a high number of steps per day. More evidence is needed to
determine if an exercise program designed to increase step count will decrease the
amount of IMAT volume and enhance muscle performance and physical function.
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Table 1. Values are mean (SD) unless otherwise indicated

Step
Count
(steps/day)

N

Gender
(M/F)

Duration Vibration
Average
Muscle
6MW
PFPT
of
Perception
IMAT
Volume PPT
BMI
HbA1c
Step Count
3
(feet)
(ft lbs)
Diabetes Threshold
(cm )
(cm3)
(steps/day)
(yrs)
(Volts)
68(14) 35.5(6.7) 7.0(1.2)
11(6)
42(10)
3995(624) 157(127)* 735(206) 26(5) 1147(300)* 33.3(12.5)
69(10) 30.5(6.1) 6.9(0.4)
11(9)
39(11)
6310(1032)
53(27)
811(253) 30(2) 1564(244) 42.7(10.5)
55(11)* 33.9(6.2) 7.4(2.2)
11(7)
40(11)
13162(4645)
44(22)
880(66) 29(3) 1471(346) 44.1(7.9)
0.05
0.30
0.78
0.98
0.86
<0.00#
0.02
0.40
0.07
0.04
0.13
Age
(yrs)

<5000
7
4/3
5000-8000 8
6/2
>8000
7
5/2
P values
Full
22 15/7
65(13) 33.2(6.4) 7.1(1.4)
11(7)
40(10)
7754(4678)
84(88)
Range
P values are from the ANOVA results between the 3 different groups based on activity level.

809(196) 28(4)

1402(336)
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PPT=modified 9-item physical performance test score; 6MW=six minute walk distance; IMAT=intermuscular adipose tissue volume
in the calf; PFPT=plantarflexor peak torque
* indicates difference from other 2 groups based on post hoc t-tests from ANOVA results (P<0.05)
# indicates all 3 groups are different from each other based on post hoc t-tests from ANOVA results (P<0.05)

40.1(11.1)

Table 2—multiple regression analysis results for Step Count as dependent variable.
R
R Square R Square Change Sig. F Change
IMAT
0.44
0.19
0.19
0.04
Age
0.51
0.26
0.07
0.19
BMI
0.53
0.28
0.02
0.51
HbA1c
0.61
0.38
0.10
0.13
DM Duration
0.61
0.38
0.00
0.84
Muscle Performance
0.63
0.39
0.01
0.90
Physical Performance
0.74
0.55
0.16
0.17
IMAT=Intermuscular adipose tissue; Muscle Performance=dorsiflexion and
plantarflexion peak torque and power; Physical Performance=6 minute walk and physical
performance test scores
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Table 3—univariate correlation matrix
Steps
Age
Steps
MVol
HbA1c
PPT
6MW
IMAT
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DFPT
DFPOW
PFPT
PFPOW
DM DUR

MVol

HbA1c

PPT

6MW IMAT DFPT DFPOW

PFPT

-0.39* -0.46*

-0.54*

-0.15

-0.22

0.31

-0.20

-0.12

-0.23

-0.21

-0.04

0.36

-0.12

0.27

0.10

-0.44*

0.05

-0.02

0.19

0.18

-0.09

-0.03

0.35

0.09

0.17

-0.45* 0.69*

0.65*

0.36

0.12

-0.02

-0.03

-0.18

0.04

-0.11

0.20

0.15

0.12

0.05

0.22

-0.39*

0.75* -0.43*

-0.03

-0.08

0.55*

0.43*

-0.36

-0.08

-0.48*

0.08

0.03

0.47*

0.48*

-0.27

-0.06

-0.06

-0.02

-0.45*

-0.29

-0.05

-0.16

0.97*

0.37

0.14

0.03

0.03

0.28

0.02

0.00

0.10

0.82*

-0.35

-0.02

-0.43*

-0.08

0.23

PFPOW DM DUR

VPT

-0.01

*indicates significance P<0.05
Steps=average daily step count; MVol=muscle volume in the calf; PPT=modified 9-item physical performance test score; 6MW=six
minute walk distance; IMAT=intermuscular adipose tissue volume in the calf; DFPT=dorsiflexor peak torque; DFPOW=dorsiflexor
power; PFPT=plantarflexor peak torque; PFPOW=plantarflexor power; DM DUR=duration of time with diabetes; VPT=vibration
perception threshold (measure of neuropathy)

Figure 1

57

References
1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General
information and national estimates on diabetes in the United States, 2007. Atlanta, GA:
US Dept of Health and Human Services.
2. Smith AG, Russell J, Feldman EL, Goldsten J, Peltier A, Smith S, Hamwi J, Pollari D,
Bixby B, Howard J, Singleton JR. Lifestyle intervention for pre-diabetic neuropathy.
Diabetes Care. 2006; 29(6):1294-9.
3. Ryerson B, Tierney EF, Thompson TJ, Engelgau MM, Wang J, Gregg EW, Geiss LS.
Excess physical limitations among adults with diabetes in the U.S. population, 19971999. Diabetes Care. 2003; 26(1):206-210.
4. Hilton TN, Tuttle LJ, Bohnert KL, Mueller MJ, Sinacore DR. Excessive adipose tissue
infiltration in skeletal muscle in individuals with obesity, diabetes mellitus, and
peripheral neuropathy: Association with performance and function. Phys Ther. 2008;
88(11):1336-44.
5. Ruan XY, Gallagher D, Harris T, Albu J, Heymsfield S, Kuznia P, Heshka S.
Estimating whole body intermuscular adipose tissue from single cross-sectional magnetic
resonance images. J Appl Physiol. 2007;102:748-754.
6. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm
E, Newman AB. Attenuation of skeletal muscle and strength in the elderly: The Health
ABC Study. J Appl Physiol. 2001; 90(6):2157-65.
7. Manini TM, Clark BC, Nalls MA, Goodpaster BH, Ploutz-Snyder LL, Harris TB.
Reduced physical activity increases intermuscular adipose tissue in healthy young adults.
J Appl Physiol. 2007; 103(1):21-7.
8. Marcus RL, Smith S, Morrell G et al. Comparison of combine aerobic and high force
eccentric resistance exercise with aerobic only exercise for people with type 2 diabetes
mellitus. Phys Ther. 2008;88(11):1345-54.
9. Ryan AS, Dobrovolny CL, Smith GV, Silver KH, Macko RF. Hemiparetic muscle
atrophy and increased intramuscular fat in stroke patients. Arch Phys Med Rehabil.
2002;83(12):1703-7.
10. Gorgey AS, Dudley GA. Skeletal muscle atrophy and increased intramuscular fat
after incomplete spinal cord injury. Spinal Cord. 2007;45(4):304-9.
11. Rowshan K, Hadley S, Pham K, Caiozzo V, Lee TQ, Gupta R. Development of fatty
atrophy after neurologic and rotator cuff injuries in an animal model of rotator cuff
pathology. J Bone Joint Surg Am. 2010; 92:2270-8.
58

12. Goodpaster, BH, Thaete FL, Simoneau J-A, and Kelley DE. Subcutaneous abdominal
fat and thigh muscle composition predict insulin sensitivity independently of visceral fat.
Diabetes. 1997; 46: 1579-1585.
13. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical
activity/exercise and type 2 diabetes – A consensus statement from the American diabetes
association. Diabetes Care. 2006;29(6):1433-8.
14. LeMaster JW, Reiber GE, Smith DG, Heagerty PJ, Wallace C. Daily weight-bearing
activity does not increase the risk of diabetic foot ulcers. Med Sci Sports Exerc.
2003;35(7):1093-9.
15. Armstrong DG, Lavery LA, Holtz-Neiderer K, Mohler MJ, Wendel CS, Nixon BP,
Boulton AJ. Variability in activity may precede diabetic foot ulceration. Diabetes Care.
2004;27(8):1980-4.
16. Maluf KS, Mueller MJ. Comparison of physical activity and cumulative plantar tissue
stress among subjects with and without diabetes mellitus and a history of recurrent
plantar ulcers. Clinical Biomechanics. 2003;18(7):567-75.
17. Diamond JE, Mueller MJ, Delitto A, Sinacore DR. Reliability of a diabetic foot
evaluation. Phys Ther. 1989;69(10):797-802.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function
Laboratories. ATS Statement: Guidelines for the Six-Minute walk test. Am J Respir Crit
Care Med. 2002;166(1):111-7.
19. Beriault K, Carpentier AC, Gagnon C, Menard J, Baillargeon JP, Ardilouze JL,
Langlois MF. Reproducibility of the 6-minute walk test in obese adults. Int J Sports
Med. 2009;30(10):725-7.
20. Brown M, Sinacore DR, Binder EF, Kohrt WM. Physical and performance measures
for the identification of mild to moderate frailty. J Gerontol A Biol Sci Med Sci.
2000;55:M350-M355.
21. Binder EF, Birge SJ, Spina R, Ehsani AA, Brown M, Sinacore DR, KohrtWM. Peak
aerobic power is an important component of physical performance in older women. J
Gerontol A Biol Sci Med Sci. 1999;54:M353-M356.
22. Brown M, Sinacore DR, Ehsani AA, Binder EF, Holloszy JO, Kohrt WM. Lowintensity exercise as a modifier of physical frailty in older adults. Arch Phys Med
Rehabil. 2000;81:960-965.
23. Goodpaster BH, Krishnaswami S, Harris TB, et al. Obesity, regional body fat
distribution, and the metabolic syndrome in older men and women. Arch Intern Med.
2005;165(7):777-83.

59

24. Gallagher D, Kelley DE, Yim JE, et al. Adipose tissue distribution is different in type
2 diabetes. Am J Clin Nutr. 2009; 89(3):807-14.
25. Boettcher M, Machann J, Stefan N, et al. Intermuscular adipose tissue (IMAT):
association with other adipose tissue compartments and insulin sensitivity. J Magn
Reson Imaging. 2009;29(6):1340-5.
26. Zoico E, Rossi A, Di Francesco V, et al. Adipose tissue infiltration in skeletal muscle
of healthy elderly men: relationships with body composition, insulin resistance, and
inflammation at the systemic and tissue level. J Gerontol A Biol Sci Med Sci.
2010;65(3):295-9.
27. Mazzali G, Di Francesco V, Zoico E, et al. Interrelations between fat distribution,
muscle lipid content, adipcytokines, and insulin resistance: effect of moderate weight loss
in older women. Am J Clin Nutr. 2006;84(5):1193-9.
28. Goodpaster BH, Chomentowski P, Ward BK, et al. Effects of physical activity on
strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial.
J Appl Physiol. 2008;105(5):1498-503.
29. Amati F, Dubé JJ, Coen PM, Stefanovic-Racic M, Toledo FG, Goodpaster BH.
Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care.
2009;32(8):1547-9.
30. Santanasto AJ, Glynn NW, Newman MA, et al. Impact of weight loss on physical
function with changes in strength, muscle mass, and muscle fat infiltration in overweight
to moderately obese older adults: a randomized clinical trial. J Obes. 2011.
31. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American
College of Sports Medicine and the American Diabetes joint position statement.
Diabetes Care. 2010;33(12):e147-e167.
32. Kanade RV, van Deursen RWM, Harding K, Price P. Walking performance in
people with diabetic neuropathy: benefits and threats. Diabetologia. 2006; 49: 17471754.

60

Chapter 4
People with Diabetes and Peripheral Neuropathy are able to exercise safely and
increase Six Minute Walk Distance

Tuttle LJ, Hastings MK, Mueller MJ. People with Diabetes and Peripheral Neuropathy
are able to exercise safely and increase Six Minute Walk Distance.
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ABSTRACT
OBJECTIVE— The purpose of this study was to determine the effect of a 12 week
progressive walking exercise program on physical performance (Physical Performance
Test, 6 minute walk test), calf muscle performance (dorsiflexor and plantarflexor peak
torque), and calf muscle structure and composition (intermuscular adipose tissue [IMAT],
muscle volume) in people with diabetes and peripheral neuropathy (DM+PN) who
complete the 12 weeks of training (EX group) and compare these outcomes to a group of
people with DM+PN who do not complete the training (CON group).
RESEARCH DESIGN AND METHODS— Ten subjects in the EX group were
compared to 10 subjects in the CON group, all with diabetes and peripheral neuropathy
[14 men/6 women; aged 66(12); BMI 36(7)]. Modified 9-item Physical Performance
Test, 6 minute walk distance, isokinetic dynamometry of the ankle muscles, and calf
IMAT volume (via MRI) were measured.
RESULTS— Following the 12 week exercise intervention, the EX group had a
significant increase in the six minute walk distance [1266(263) to 1352(286) feet]
compared to the CON group [1409 (293) to 1398 (234) feet] (P<0.05). There were no
other significant differences between the groups.
CONCLUSIONS—People with diabetes and peripheral neuropathy are able to tolerate a
progressive walking and exercise program and increase six minute walk distance. They
showed no significant calf muscle changes with this mild exercise intensity.
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The benefits of exercise to help control diabetes mellitus (DM) and reduce
subsequent complications are well known and accepted (1).

In addition to improved

DM control and lower mortality rates, walking and increased activity appears to improve
complications such as neuropathic pain from peripheral neuropathy (PN) (2). The
evidence of the benefits of exercise for people with DM has led the American Diabetes
Association (ADA) and the American College of Sports Medicine (ACSM) (1) to
recommend that adults with DM participate in at least 30 minutes per day of moderateintensity physical activity, but the effects of this exercise program is not well known in
people with DM+PN.
People with DM+PN have reduced ankle muscle strength and volume with plantar flexor
peak torque values in people with DM+PN being about 50% of that in people without DM+PN
(3-5). Calf muscle strength is decreased and declines more rapidly in individuals with DM + PN
compared to muscular changes associated with normal aging (5). The lower extremity
musculature of individuals with DM+PN also demonstrates substantial intermuscular adipose
tissue (IMAT) infiltration and muscle atrophy as measured by magnetic resonance imaging
compared to people without DM+PN (6). Intermuscular adipose tissue (IMAT) is defined as the
visible extra-cellular adipose tissue that is located beneath the muscle fascia and between and
within muscle groups (7). It has been demonstrated that IMAT in the thigh is sensitive to changes
in activity and exercise programs in an older population (7) as well as in a group with DM (8), but
it is unclear whether an exercise program can impact IMAT or lean muscle volume in the calf of
people with DM+PN.
Although people with DM+PN clearly have lower extremity impairments, little evidence
exists to determine if these impairments can improve with exercise. The Centers for Disease
63

Control and Prevention reports adults with DM compared to those without have an odds ratio of
2.0 for having mobility limitations. The incidence of impaired mobility increases with peripheral
artery disease and/or peripheral neuropathy; subjects with DM and lower extremity diseases had an
almost 3-fold increase in risk of impaired mobility compared to those having neither (9).

The

most frequently reported mobility limitations were related to patients’ inability to walk a quarter
mile and to walk up 10 steps without resting (9). The ADA and ACSM have recently reported that
individuals with peripheral neuropathy and without acute ulceration may participate in moderate
weight-bearing exercise (1) and previous studies (10) have indicated that people with DM+PN
were able to participate in a low-intensity walking program without increasing risk of ulceration.
It is unclear exactly what “moderate weight-bearing exercise” entails and how that might affect
physical function and strength in people with DM+PN. A previous study investigating the effects
of exercise in people with DM+PN reported no strength changes with a low-intensity exercise
program (11) and a Cochrane review of the literature concluded that there is inadequate evidence
to evaluate the effect of strengthening exercise for people with DM+PN (12).
The purpose of this study was to determine the effect of a 12 week progressive walking
exercise program on physical performance (Physical Performance Test, 6 minute walk test), calf
muscle performance (dorsiflexor and plantarflexor peak torque), and calf muscle structure and
composition (IMAT, muscle volume) in people with DM+PN who participated in the 12 weeks of
training (EX group) and compare these outcomes to a group of people with DM+PN who do not
complete the training (CON group). We hypothesized that 1) the EX group would display
improved physical performance compared to the CON group 2) the EX group would display
increased dorsiflexor and plantarflexor peak torque after a progressive exercise program compared
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to the CON group and 3) the EX group would display decreased IMAT in calf muscles and
increased calf muscle volume after a progressive exercise program compared to the CON group.
Research Design and Methods
A total of 20 people with DM + PN (14 men/6 women; aged 66+12; BMI 36+7)
are reported in this study which was a portion of a larger randomized controlled clinical
trial involving exercise for people with DM+PN. The primary reason for studying this
subgroup was to use MRI to investigate muscle changes secondary to the progressive
exercise program. Participant characteristics by group are listed in Table 1. Participants
were excluded if they 1) weighed more than 300 pounds (equipment weight limit), 2) had
a history of severe foot deformity or amputation, 3) had any co-morbidity or medications
that would interfere with exercise, 4) did not have peripheral neuropathy, 5) were
currently exercising regularly, 6) had a step count less than 2,000 steps per day or greater
than 10,000 steps per day on average (screened with the StepWatch accelerometer over 7
days), 7) or if they had a current foot ulcer; none of the participants in this study had a
history of foot ulcer. Participants provided written informed consent. This study was
approved by the Human Research Protection Office at Washington University in St.
Louis.
Peripheral Neuropathy
Presence of peripheral neuropathy was determined based on an inability to feel
the 5.07 Semmes-Weinstein monofilament on at least one point on the plantar surface of
the foot and based on a vibration perception threshold of greater than 25V as measured
with a biothesiometer (13,14).
Six Minute Walk Test
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All participants performed the six minute walk test (15) as a measure of physical
function and walking endurance. The test has been validated in obese adults (16). The
participants walked back and forth in a hallway between 2 cones that were placed 100
feet apart. The participants were told that the goal was to walk as far as possible in 6
minutes. Six minute walk distance was recorded as total distance walked in feet.
Physical Performance Test (PPT)
The modified 9-item PPT was used to assess physical function in all participants.
This test is designed to mimic activities of daily living and includes items such as stair
climbing, and coming sit-to-stand. The 9-item PPT has been shown to correlate well with
disability and frailty (17). Each of the items is scored on a scale of 0-4 based on the time
it takes to complete the task. Each task is performed twice and the average time is used to
determine the 0-4 score. A maximum score is indicated by a score of 36.
Intermuscular Adipose Tissue (IMAT) and Muscle Volumes
Intermuscular adipose tissue and lean muscle volumes were quantified using MRI
on the right leg of each participant. The MRI scans were performed with the participant
in a supine position with a Siemens CP extremity coil placed over the right calf muscle.
The MRI measurements were performed with a 3.0-Tessla superconducting MRI
instrument with a pulse sequence of TE=12 milliseconds, TR=1,500 milliseconds,
matrix=256x256; both a fat saturated and a non fat saturated image were collected (6).
Thirty transverse slices were collected beginning at the joint space of the knee and
proceeding distally. The slices were 7mm thick with no interslice gap. Nine consecutive
slices were selected to calculate muscle and IMAT volumes. Volumes were quantified
using a PC workstation and custom Matlab software. The software uses voxel brightness
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to distinguish between muscle and adipose tissues. The subcutaneous adipose tissue was
removed from each image by drawing a line along the deep fascial plane surrounding the
calf muscle so that only the fat within and between the muscles (IMAT) was remaining.
The software uses edge detection algorithms to assist the user in separating the
subcutaneous fat from the muscle as well as separating individual muscles and muscle
compartments. IMAT and muscle volumes are reported in cm3. Based on test-retest
reliability of 21 subjects, the error in measuring muscle volume is less than 1% and less
than 2% for measuring fat volumes on average in any muscle or compartment.
Ankle Dorsiflexion and Plantarflexion Peak Torque
Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque as measures
of muscle performance were assessed using a Biodex Multijoint System 3 Pro isokinetic
dynamometer (Biodex Medical Systems, Shirley, NY). The tests were performed at
angular velocities of 60○/s. All participants were given 3 practice trials to ensure they
were comfortable with the test. The mean values for peak torque were calculated for 3
trials.
Activity Monitoring
Participants were given an activity monitor (StepWatch by Orthocare) and were
instructed to wear the monitor around their ankle during all waking hours to determine
baseline activity levels. The participants were given the monitor for at least 9
consecutive days calculating an average of 7 days. The first and last days of wear were
deleted because a full 24 hours would not be recorded. For a day to be included, the
monitor had to be worn for at least 8 hours, and at least 1 weekend day was included in
the 7 day average. The device records strides per day and steps per day were calculated
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by multiplying strides by 2 (1 stride equals 2 steps). Results of validity tests performed
in our laboratory indicate a mean absolute error of 1.1% (SD, 3.1%) for healthy obese
subjects and 1.8% (SD, 2.4%) for subjects with DM+PN (13). Results of the activity
monitor were used to screen subjects who were inactive or already too active (i.e.
walking less than 2,000 steps per day or greater than 10,000 steps per day) and to
prescribe specific walking distance to start their progressive walking program as
described below.
Exercise Program
The 20 participants were randomly assigned to CON or EX condition.
Randomization methods were successful as there were no differences between the groups
on the primary outcome variables before the study (P>0.05). Subjects who were assigned
to the CON group were given an opportunity to participate in the EX program after their
12 weeks in the CON group. Five subjects participated in both the CON and EX groups.
The CON group received foot screenings and education regarding foot care every two
weeks over a twelve week period for a total of 6 visits. The EX group participated in a
weightbearing exercise program three times a week for twelve weeks. The exercises
included in this program were adapted from the “Feet First” intervention (10), and those
used in prior interventions that reduced falls in frail older adults and those with peripheral
neuropathy (18). Where progression for an activity was not described in the published
study, we added an appropriate exercise progression to maximize progressive
improvements. Activity performance was supervised by a physical therapist. The
exercise sessions began with flexibility and stretching exercises. The balance exercises
followed a progressively challenging program in which external support decreased and/or
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the perturbation to a balanced individual increased (e.g. more compliant surface,
movement of arms/legs). The strengthening exercises were focused on the ankle
dorsiflexor and plantarflexor muscles for both groups using body weight resistance (i.e.
heel raises, bilateral progressing to unilateral for the plantar flexor muscles; stairclimbing and coming sit-to-stand for hip, knee, and ankle extensor muscles) rather than
machines or weights in an effort to make the exercises easier to continue after the end of
the study.
The aerobic intervention included walking on a treadmill for a duration
individually calculated for the subject based on their own average step count collected
over 7 days using a Step Watch Activity Monitor as described above. The goal was for
subjects to increase their average step count 10% every 2 weeks by increasing their daily
step count 24% on the 3 days that they participated in the exercise program. For
example, a subject with a beginning average step count of 5950 step/day had a 2 week
goal to walk an average of 6548 step/day. This goal would be achieved by walking at
their self-selected pace (40-60% estimated heart rate) an additional 1428 steps (about 14
minutes) on each of the 3 treatment days and with no change in regular activity on the
other 4 days. This modest increase in activity (10% increase every 2 weeks) would result
in the subject walking approximately 10,700 steps/day at the end of 12 weeks (~80%
increase), and would meet the surgeon general’s expectation for 10,000 steps per day and
the ADA’s guideline for 30 min/day of walking on most days. Subjects wore a heart rate
monitor to assist the physical therapist in assuring that the exercise intensity was within
the mild/moderate range (40-60% of max heart rate). Exercise participation was
modified, postponed, or stopped based on guidelines established by the ADA and ACSM
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(1). Exercise was postponed if 1) blood glucose >300 mg/dl, 2) resting systolic BP of
>200 mm Hg, 3) resting diastolic BP of >110 mm hg. If blood glucose was <80-100mg/dl
carbohydrates were ingested.
Precautions to avoid skin injury
Before and after each exercise session, the physical therapist and the participant
each performed a visual inspection of the participant’s feet and footwear. A digital
photograph was taken before and after the exercise session to document the skin
condition. Foot skin temperature was recorded using a handheld infrared thermometer
(Xilas) before and after each session as described previously (19). The temperature was
recorded at 7 sites on the plantar surface of the foot where risk for skin breakdown is
greatest: the great toe, the 1st, 3rd, and 5th metatarsal heads, medial and lateral midfoot,
and the heel. The temperature measures were used to determine areas that might be at
risk for injury and were part of a composite assessment for skin injury that included
redness, swelling and pain. If there was an area of redness, swelling, pain and increased
temperature, activity was limited and the participant was instructed to closely monitor the
area and decrease daily activity.
Data Analysis
Statistical analyses were performed using Systat for windows, version 13.0. A
repeated measures ANOVA was performed to determine any group by time interactions.
Significance was set at P<0.05.

Results
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Following the 12 week exercise intervention, the EX group had a significant
improvement in the six minute walk distance compared to the CON group. The EX group
was able to increase six minute walk distance from 1266 feet to 1352 feet while the CON
group changed from 1409 feet to 1398 feet (P=0.04). Table 2. There was no difference in
PPT scores after a 12 week exercise program (EX 27 to 29 vs. CON 29 to 30) . There was
no difference in measures of dorsiflexor peak torque (EX 6.8 to 7.7 vs. CON 5.3 to 3.6
Nm) or plantarflexor peak torque (EX 51.9 to 56.9 vs. CON 54.2 to 57.8 Nm) after a 12
week exercise program. There was no significant difference in IMAT volumes (EX 100
to 103 vs. CON 84 to 93 cm3) or calf muscle volumes (EX 431 to 425 vs. CON 424 to
420 cm3) after a 12 week exercise program (P>0.05).

Conclusions
In this study, we found that a group of people with DM+PN were able to tolerate
a 12 week progressive exercise program and were able to increase their 6 minute walk
distance, but showed few other measured changes in calf muscle structure, strength or
physical performance. Lord et al (20) and Harada et al (21) demonstrated that 6 minute
walk distance appears to provide a measure of overall mobility and physical functioning
in an older population rather than a specific measure of cardiovascular fitness which
indicates that the EX group improved mobility and physical functioning overall in
comparison to the CON group. However, the average 6 minute walk distance for healthy
55-75 year olds has been reported to be 2161 feet (22), so even with this improvement in
six minute walk distance, the EX group with DM+PN is still limited in comparison to
healthy controls. While the EX group continues to have limitations in comparison to
healthy controls, the change in six minute walk distance is consistent with a meaningful
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change (>20m or >66 feet) as reported by Perera et al. (23). The change in six minute
walk distance that we report is consistent with another recent study involving supervised
walking in people with diabetes, but without peripheral neuropathy (24). This study by
Negri et al. reports changes in six minute walk distance that are larger than what we
report here, but it is important to note that people with diabetes and neuropathy are able
to increase six minute walk distance like their peers without neuropathy.
The EX group was able to tolerate the 12 week exercise program and increase
their six minute walk distance with a minimum of complications. The EX group attended
an average of 85% of the exercise sessions with a total of 4 foot-related complications.
One person had an injury from trimming his own toenails, one person had a small
abrasion on the second metatarsal head from walking barefoot at home that resolved
within 3 days, and one person had a full-thickness wound on the 5th metatarsal head that
appeared after callus was removed during a visit to the podiatrist. One person suffered a
calf strain during exercise, but was able to continue to exercise with a lower intensity
(shorter time on treadmill, fewer heel raises) and the strain resolved within one week.
The CON group had two foot-related complications. One person had a cut on the great
toe due to walking barefoot at home, and one person had an open lesion between the 4th
and 5th toe. Both lesions resolved within 2 weeks. The annual population based incidence
of diabetic full-thickness foot ulcers ranges from 1.0-4.1% (25). Due to a relatively low
incidence rate of ulceration, we are unable to truly detect differences in ulceration rates in
this small sample. We believe the daily pre-post exercise visual inspection to the feet
helped to minimize skin injury. In addition, it has been reported (26) that high variability
in activity may contribute to plantar ulceration in people with DM+PN. It is possible that
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consistently attending the exercise sessions and monitoring overall activity helped to
maintain a consistent activity level and reduced the risk of ulceration in this study
population.
While six minute walk distance improved in the EX group as expected, we had
several unexpected findings from this study. The 12 week progressive exercise program
did not have a measureable impact on calf muscle volume, IMAT volume, dorsiflexor or
plantarflexor peak torque. Physical performance as measured by PPT score was also
unchanged after exercise, which is different from what we had expected. Other
investigators have reported significant reduction in IMAT, increased muscle mass in the
thigh and increased muscle strength after an exercise program for people with diabetes
who do not have peripheral neuropathy (8). This study involved the use of eccentric
exercise and higher resistance than in our study. In our study, we did not find changes in
IMAT, muscle, or muscle strength in the calf after an exercise program. It is possible
that the intensity of our strengthening exercises was not sufficient to cause changes like
those that Marcus et al. report. Our study population was specifically people with
diabetes and peripheral neuropathy rather than those with diabetes alone, so it is possible
that the presence of neuropathy minimized the ability of the calf muscles to respond to
the exercise program in the manner that we anticipated.
Goodpaster et al (7) has reported that older adults who participate in an exercise
program that uses walking as a main intervention were able to maintain muscle strength
and minimize IMAT infiltration in comparison to a group who did not exercise. In that
study, the comparison group lost strength and gained IMAT, whereas our CON group
remained unchanged in these measures. In that particular study, the exercise intervention
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was for one year rather than 12 weeks, so it is possible that with a longer intervention or
longer follow up, we might have noticed similar results (i.e. greater decline in CON
group and maintenance of muscle strength in EX group). As in the Marcus study,
Goodpaster et al measured IMAT and muscle in the thigh rather than the calf. Other
investigators (5) have noted that people with diabetes and peripheral neuropathy have
more severe involvement distally compared to proximally. It is possible that our
intervention could have had an effect on the thigh, but we did not measure thigh changes
in this particular study.
In the “Feet First” randomized controlled trial (11), a population with DM + PN
participated in an exercise program and was followed for one year. These investigators
also did not see a change in muscle strength, but the intensity of the walking program and
the strengthening exercises were less than in our study. In addition, part of their study
was done by the participants at home and the authors report that compliance with the
exercise was a problem, which could have limited the potential to observe meaningful
changes in this population. We had a compliance rate of 85% in this study, so we believe
that the lack of changes that we report is not due to poor compliance.
This study provides important information about exercise in people with DM +
PN, but there are limitations that should be considered. First, this study has a small
sample size and was not powered to detect subtle changes in outcome measures.
Furthermore, we included only people already walking 2000-9000 steps per day and it is
unknown whether these results apply to people with more severe involvement or DM
complications. Also, there were 5 people who were in the CON group who then
completed the exercise intervention, so these groups are not truly independent of each
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other. In addition, we did not measure the thigh muscle or thigh muscle performance, so
it is possible that the exercise program had an effect on the lower extremities that we are
not capturing. Our measures of IMAT and muscle volume are gross morphological
measures, and we do not have a measure of changes that might be occurring on a smaller
scale such as mitochondrial function in the muscle. Finally, we do not have a follow up
on these subjects beyond the end of the exercise program, so we are unable to comment
on the longer term effects of the exercise program compared to those who do not
exercise.
Despite these limitations, this study provides evidence that people with DM + PN
are able to participate in a progressive walking and strengthening program and
demonstrate improved overall mobility and function based on six minute walk distance.
These findings are consistent with the recently updated ADA guidelines indicating that
individuals with DM+PN and without acute ulceration may participate in moderate
weight-bearing exercise (1). Future studies that include a larger number of subjects
receiving a higher intensity of resistance exercise than used in this study, and evaluating
all lower extremity muscles, are needed to determine the appropriate safe dosage and
intensity of activity to optimize changes in muscle morphology, strength, and physical
mobility measures in this population.
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Table 1. Subject Characteristics. Values are means(SD).

Group

N

Gender
(M/F)

Age
(yrs)

Weight
(lbs)

BMI
(kg/m2)

HbA1c
(%)

DM
Duration
(years)

EX
CON

10
10

8/2
6/4

68(9)
66(14)

246(41)
242(57)

35.5(6)
36.5(8)

6.8(0.9)
7.7(2.2)

11.6(7.7)
10.3(5.5)
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Vibration
Perception
Threshold
(V)
40(11)
37(11)

Table 2. Group Data Pre and Post Exercise. Values are Mean (SD)
Pre
Post
6MW (feet)*
EX Group
1266 (263)
1352 (286)
CON Group
1409 (293)
1398 (234)
PPT
EX Group
27 (5)
29 (5)
CON Group
29 (3)
30 (3)
3
Muscle Volume (cm )
EX Group
431 (89)
425 (108)
CON Group
424 (128)
420 (116)
3
IMAT (cm )
EX Group
100 (51)
103 (50)
CON Group
84 (50)
93 (50)
DF PT (Nm)
EX Group
6.8 (13.3)
7.7 (9.1)
CON Group
5.3 (6.8)
3.6 (3.2)
PF PT (Nm)
EX Group
51.9 (20.2)
56.9 (28.7)
CON Group
54.2 (16.7)
57.8 (26.4)
*Indicates significant Group x Time interaction based on repeated measures ANOVA and
significant post hoc difference between pre and post measures (P<0.05)
The groups were not different from each other on any pre test measures (P>0.05)
6MW=6 minute walk distance
PPT=modified physical performance test score
Muscle volume=calf muscle volume measured via MRI
IMAT=intermuscular adipose tissue volume measured via MRI
DF PT=dorsiflexor peak torque
PF PT= plantarflexor peak torque
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Chapter 5
A weight-bearing exercise program for people with diabetes and peripheral
neuropathy: A case report

This chapter is in review:
Tuttle LJ, Hastings MK, Mueller MJ. A weight-bearing exercise program for people with
diabetes and peripheral neuropathy: A case report. Phys Ther.
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ABSTRACT
Background and Purpose
The exercise guidelines for people with diabetes mellitus and peripheral neuropathy
(DM+PN) have recently changed to allow moderate intensity weight-bearing exercise,
but there are few reports in the literature describing appropriate weight-bearing exercise
for those with DM+PN. This case report describes a successful and safe progressive
exercise program for an individual with DM+PN.
Case Description
The subject was a 76 year old man with a 30 year history of DM + PN. He participated in
a 12 week progressive exercise program (3 times per week) involving walking on a
treadmill, balance exercises, and strengthening exercises for the lower extremities using
body weight resistance.
Outcomes
Measures were taken before and after the 12 weeks of exercise. Six minute walk distance
increased from 1200 to 1470 feet. Physical performance test score changed from 29 to 30.
The Foot and Ankle Ability Measure questionnaire improved from 89-98. Dorsiflexor
and plantarflexor peak torque increased (right dorsiflexor peak torque: 4.5 to 4.6 Nm, left
dorsiflexor peak torque:2.8 to 3.8 Nm; right plantarflexor peak torque: 44.7 to 62.4 Nm,
left plantarflexor peak torque: 40.8 to 56.0 Nm), as did his average daily step count (6176
to 8273 ave steps/day). Calf intermuscular adipose tissue changed from 48 to 56 cm3 and
calf muscle volume changed from 426 to 390 cm3.
Discussion and Conclusions
Evidence from this case report provides clinicians with a potential exercise program for
people with DM+PN that may be able to increase muscle strength, physical function and
activity.
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People with diabetes and peripheral neuropathy (DM+PN) clearly have lower
extremity impairments including reduced ankle muscle strength and volume.1-3 Evidence
suggests that the lower extremity muscles in people with DM+PN have substantial
intermuscular adipose tissue (the visible extra-cellular adipose tissue that is located
beneath the muscle fascia and between and within muscle groups4 [IMAT]) and muscle
atrophy compared to their peers.5
These muscle changes likely contribute to their limitations in physical mobility.
Adults with DM have an odds ratio of 2.0 for having mobility limitations compared to
those without DM.6 The incidence of impaired mobility increases with peripheral artery
disease and/or PN; subjects with DM and lower extremity diseases had an almost 3-fold
increase in risk of impaired mobility compared to those having neither.6 An inability to
walk a quarter mile and to walk up 10 steps without resting are the most frequently
reported mobility limitations.6 Little evidence exists to determine if these impairments
in muscle and mobility can improve with exercise.
In addition to these documented limitations in physical mobility, individuals with
DM+PN lack the critical level of sensory feedback to protect their feet from injury.
Historically, their inability to monitor their own skin condition led the ADA and ACSM
to recommend exercise that was restricted to non-weight bearing activities (2006
guidelines). The exercise guidelines have recently changed, however, to allow
individuals with DM+PN and without acute ulceration to participate in moderate weightbearing exercise.7 This change was prompted, in part, by the recent “Feet First”
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randomized controlled clinical trial8 that reported that people with DM+PN were able to
participate in a low-intensity walking program and show a slight improvement in daily
walking activity without increasing their rate of ulceration. Despite the benefits of this
study, this same “Feet First” study reported no lower extremity strength changes with
their low-intensity, community based exercise program9 and a Cochrane review of the
literature concluded that there is inadequate evidence to evaluate the effect of
strengthening exercise for people with DM+PN.10 Because the intervention intensity
was quite low in the previous reports, it is unclear if people with DM+PN are able to
increase lower extremity strength or reduce mobility impairments with an appropriately
dosed exercise program.
The purpose of this case report is to describe the effects of a 12 week progressive
walking and resistance exercise program on physical performance (6 minute walk test,
Physical Performance Test, Foot and Ankle Ability Measure), calf muscle performance
(dorsiflexor and plantarflexor peak torque), and calf muscle structure and composition
(IMAT, muscle volume) in a single individual with DM+PN.
Case Description
Background to the case report
The case reported here is from an individual who participated in a randomized
controlled trial comparing weight-bearing exercise, non weight-bearing exercise, and a
non-exercising condition for people who have DM+PN. The overall goal of the trial is to
determine whether people with DM+PN are able to perform weight-bearing exercise to
increase activity level and physical mobility without increasing the incidence of foot
ulcers or skin breakdown. The subject provided written informed consent and the study
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was approved by the Human Research Protection Office at Washington University in St.
Louis.

Patient
The subject was a 76 y.o. man, with a BMI of 27.1, with a 30 year history of Type
2 DM. His comorbid conditions included a history of myocardial infarction, history of
coronary artery bypass graft, and hypertension that was controlled with medication. His
blood sugar was controlled through oral medication.
Tests and Measures
Peripheral Neuropathy (PN)
The subject had severe PN based on his inability to feel any Semmes-Weinstein
monofilament on the plantar surface of the foot and based on his vibration perception
threshold of 50V as measured with a biothesiometer (threshold for neuropathy is 25V, 50
V is maximum value of machine).11,12
Six Minute Walk Test
The participant performed the six minute walk test13 as a measure of physical
function and walking endurance. The test has been validated in obese adults.14 The
participant walked back and forth in a hallway between 2 cones that were placed 100 feet
apart. The participant was told that the goal was to walk as far as possible in 6 minutes.
Six minute walk distance was recorded as total distance walked in feet.
Physical Performance Test (PPT)
The modified 9-item PPT was used to assess physical function. This test is
designed to mimic activities of daily living and includes items such as stair climbing, and
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coming sit-to-stand. The 9-item PPT has been shown to correlate well with disability and
frailty.15 Each of the items is scored on a scale of 0-4 based on the time it takes to
complete the task. Each task is performed twice and the average time is used to determine
the 0-4 score. A maximum score is indicated by a score of 36.
Foot and Ankle Ability Measure (FAAM)
The FAAM is a reliable, responsive, and valid self-report measure of physical
function for individuals with a broad range of musculoskeletal disorders of the lower leg,
foot, and ankle.16 The questions investigate the subjects perception of 26 activities of
daily living (i.e. walking on even ground, walking up hills, stepping up and down curbs,
home responsibilities, recreational activities). The FAAM was found to be more
responsive to changes in functional status compared to the SF-36 and has a high testretest reliability of 0.89.16 A higher score on the FAAM indicates better physical
function.
Ankle Dorsiflexion and Plantarflexion Peak Torque
Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque as measures
of muscle performance were assessed using a Biodex Multijoint System 3 Pro isokinetic
dynamometer.†† The tests were performed at angular velocities of 60○/s. He was given 3
practice trials to ensure he was comfortable with the test. The mean values for peak
torque were calculated for 3 trials.
Intermuscular Adipose Tissue (IMAT) and Muscle Volumes
Intermuscular adipose tissue and lean muscle volumes were quantified using MRI
on the right leg. The MRI scans were performed with the participant in a supine position

††

Biodex Medical Systems, 20 Ramsay Road, Shirley, NY 11967.
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with a Siemens CP extremity coil placed over the right calf muscle. The MRI
measurements were performed with a 3.0-Tessla magnet‡‡ with a pulse sequence of
TE=12 milliseconds, TR=1,500 milliseconds, matrix=256x256; both a fat saturated and a
non fat saturated image were collected.5 Thirty transverse slices were collected
beginning at the joint space of the knee and proceeding distally. The slices were 7mm
thick with no interslice gap. Nine consecutive slices were selected to calculate muscle
and IMAT volumes. Volumes were quantified using a PC workstation and custom
Matlab software. The software uses voxel brightness to distinguish between muscle and
adipose tissues. The subcutaneous adipose tissue was removed from each image by
drawing a line along the deep fascial plane surrounding the calf muscle so that only the
fat within and between the muscles (IMAT) was remaining. The software uses edge
detection algorithms to assist the user in separating the subcutaneous fat from the muscle
as well as separating individual muscles and muscle compartments. IMAT and muscle
volumes are reported in cm3. Based on test-retest reliability of 21 subjects, the error in
measuring muscle volume is less than 1% and less than 2% for measuring fat volumes on
average in any muscle or compartment.
Activity Monitoring
The participant was given a StepWatch activity monitor§§ and was instructed to
wear the monitor around his ankle during all waking hours to determine baseline activity
levels. The participant was given the monitor for at least 9 consecutive days calculating
an average of 7 days. The first and last days of wear were deleted because a full 24 hours
‡‡

Siemens Corp, Citicorp Center, 153 E. 53rd St., New York, NY 10022

§§

Orthocare Innovations, 840 Research Parkway, Suite 200,Oklahoma City, OK 73104
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would not be recorded. For a day to be included, the monitor had to be worn for at least 8
hours, and at least 1 weekend day was included in the 7 day average. The device records
strides per day and steps per day were calculated by multiplying strides by 2 (1 stride
equals 2 steps). Results of validity tests performed in our laboratory indicate a mean
absolute error of 1.1% (SD, 3.1%) for healthy obese subjects and 1.8% (SD, 2.4%) for
subjects with DM+PN.11 Results of the activity monitor were used to prescribe his
specific walking distance to start his progressive walking program as described below.
The subject was determined to be appropriate for participation in this exercise
program due to the presence of DM+PN and lack of any severe foot deformities or comorbidities that might limit his ability to tolerate 60 minutes of exercise.
Exercise Program
The subject participated in a weightbearing exercise program three times a week
for twelve weeks. The exercises included in this program were adapted from the “Feet
First” intervention,8 and those used in prior interventions that reduced falls in frail older
adults and those with PN.17 Where progression for an activity was not described in the
published study, we added an appropriate exercise progression to maximize progressive
improvements. Activity performance was supervised by a physical therapist. The
exercise sessions began with flexibility and stretching exercises. The stretches included:
toe stretches aimed at stretching the toe extensor muscles, a supine hamstring stretch,
prone knee flexion, rocking on hands and knees, and a standing calf stretch. Each stretch
was performed twice with a 30 second hold. The balance exercises followed a
progressively challenging program in which external support decreased and/or the
perturbation to a balanced individual increased (e.g. more compliant surface, movement
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of arms/legs). The strengthening exercises were focused on the ankle dorsiflexor and
plantarflexor muscles using body weight resistance (i.e. heel raises, bilateral progressing
to unilateral for the plantar flexor muscles; stair-climbing and coming sit-to-stand for hip,
knee, and ankle extensor muscles) rather than machines or weights in an effort to make
the exercises easier to continue after the end of the study (Table 1).
The aerobic intervention included walking on a treadmill for a duration
individually calculated for the subject based on his own average step count collected over
7 days using a Step Watch Activity Monitor as described above. The goal was for the
subject to increase his average step count 10% every 2 weeks by increasing his daily step
count 24% on the 3 days that he participated in the exercise program. In this case, he
began with a step count of 6176 steps/day and the goal was for him to reach 10,712
steps/day (See Figure 1 for step count weekly goals). The subject wore a heart rate
monitor to assist the physical therapist in ensuring that the exercise intensity was within
the mild/moderate range (40-60% of max heart rate). Exercise participation was
modified, postponed, or stopped based on guidelines established by the ADA and
ACSM.7 Exercise was postponed if 1) blood glucose >300 mg/dl, 2) resting systolic BP
of >200 mm Hg, 3) resting diastolic BP of >110 mm hg. If blood glucose was <80100mg/dl carbohydrates were ingested.
Precautions to avoid skin injury
Before and after each exercise session, the physical therapist and the participant
each performed a visual inspection of the participant’s feet and footwear. A digital
photograph was taken before and after the exercise session to document the skin
condition. Foot skin temperature was recorded using a handheld infrared thermometer

90

(Diabetica Temptouch***) before and after each session as described previously.18 The
temperature was recorded at 7 sites on the plantar surface of the foot where risk for skin
breakdown is greatest: the great toe, the 1st, 3rd, and 5th metatarsal heads, medial and
lateral midfoot, and the heel. The temperature measures were used to determine areas
that might be at risk for injury and were part of a composite assessment for skin injury
that included redness, swelling and pain. If there was an area of redness, swelling, pain
and increased temperature, activity was limited and the participant was instructed to
closely monitor the area and decrease daily activity.
Adherence to Exercise
All exercise sessions were monitored by a physical therapist. In order to assist
with transportation costs, the subject received ten dollars for each exercise visit attended.
The subject attended 86% of the scheduled exercise classes. The subject missed 5
exercise sessions due to illness and conflict with previously scheduled doctor’s
appointments.
Outcomes
Data for outcome measures were obtained before and after the 12 week exercise
program (Table 2). He was able to progress on all of the prescribed exercises and was
able to increase his time on the treadmill at his self-selected pace of 2.0 mph from 14min
to 24min. The subject improved his six minute walk distance from 1200 to 1470 feet. His
PPT score improved from 29 to 30 and his FAAM score improved from 89-98%. The
participants average daily step count increased from 6176 to 8273 steps/day. Glucose
control improved as indicated by a decrease in HbA1c from 6.9 to 6.4%.
***

Diabetic solutions Inc. 12665 Silicon Drive, San Antonio, TX 78201
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Dorsiflexor and plantarflexor peak torque increased (right dorsiflexor peak
torque: 4.5 to 4.6 Nm, left dorsiflexor peak torque:2.8 to 3.8 Nm; right plantarflexor peak
torque: 44.7 to 62.4 Nm, left plantarflexor peak torque: 40.8 to 56.0 Nm) (Figure 1).
IMAT volume increased (48 to 56 cm3) and calf muscle volume decreased (426 to 390
cm3). He also lost 13 pounds over the 12 week intervention.
This subject was able to tolerate a 12 week exercise program without
complications or skin breakdown. His only injury came from trimming his own toe nails
and this injury resolved in less than one week.
Discussion
The guidelines from the ADA and ACSM have recently changed to indicate that
people with DM+PN may participate in moderate weight bearing exercise. Prior to this
change in guidelines, it was recommended that people with DM+PN limit weight bearing
activity due to concerns for increased risk for skin injury. This case report provides an
example of a moderate intensity, weight-bearing exercise program that was successful in
safely increasing six minute walk distance, average daily step count, and ankle strength in
a person with DM+PN.
The subject presented in this case report was able to increase his six minute walk
distance from 1200 to 1470 feet after the 12 week exercise program. The six minute
walk test has been shown to be a measure of overall mobility and physical function19,20
and a change of 270 feet is consistent with a substantial change as reported by Perera et
al.21 It seems reasonable that the six minute walk distance improved as the subject was
part of a duration based walking program. Even though he did not increase his velocity
during treadmill training, he was able to increase his velocity during the six minute walk
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test. Essentially, he was training to walk and he was successful in improving his ability to
walk.
In the case of this subject, PPT scores did not improve substantially (29-30).
Based on an initial score of 29 out of 36 possible points, this particular subject did not
demonstrate frailty or severe limitations in function, so it is possible that he had little
room to improve on the PPT measure. However, his FAAM score did improve by 9
points, which is beyond the minimal detectable change (5.7 points) and minimal
clinically important change (8 points) of the test.16 The subject reported improvements
on the FAAM in: walking uphill, climbing stairs, going up and down curbs, squatting,
doing heavy work (pushing/pulling, climbing, carrying), and in recreational activities.
The FAAM is a measure of physical function that is specific to the foot, ankle and lower
extremity activities whereas the PPT incorporates upper extremity activities as well. The
exercise program reported here is focused entirely on the lower extremity, so it is
possible that the FAAM is a more sensitive measure of improvement than the PPT in this
case.
Dorsiflexor and plantarflexor strength measures (peak torque) responded
differently from each other in this intervention. The dorsiflexor peak torque values did
not change as much as the plantarflexor peak torque, but the plantarflexor peak torque
increased by 37-40%. There are several reasons that could account for this difference in
response. First, more of the exercises in this program were focused on increasing
strength in the plantarflexors. The primary exercise for the dorsiflexors was heel stands,
while the plantarflexors had toe raises (heels up), stair climbing, and sit to stand. It has
been reported previously that dorsiflexion is impaired in people with DM+PN.3 It is
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possible that due to the process of DM and DM+PN, the dorsiflexors may be harder to
strengthen or less able to adapt than the plantaflexors.
The “Feet First” study9 described a low-intensity intervention for people with
DM+PN aimed at increasing walking activity and improving strength, but they report no
strength changes in their exercise program. The intervention that we describe here is
more intensive than the “Feet First” study based on our goal of increasing step count by
10% every 2 weeks. This subject was able to tolerate this more aggressive program
without injury or complications and was able to increase his average daily step count
from 6176 to 8273 steps per day (34% increase) (Figure 1). However, this subject did not
actually meet the target goal of increasing step count by 10% every 2 weeks (goal of
10,712 steps/day). Because he was walking at his self selected pace and we based the
walking program on a predetermined length of walking time, his actual number of steps
taken during the treadmill walk was less than what was required for the 10% increase to
occur.
While this subject was able to increase his average daily activity, ankle muscle
strength and six minute walk distance, he lost weight overall and actually lost muscle
volume in the calf and gained IMAT in the calf. Previous studies of a walking program
in older adults22 indicate that an exercise program can attenuate strength loss and IMAT
gain in the thigh. It is unknown whether people with DM+PN are able to respond in a
similar manner and it is unknown whether neuropathic muscle is able to adapt or what the
intensity of the stimulus should be to elicit change in muscle structure. Based on this
case study, it appears that change in calf muscle volume and calf IMAT volume are not
directly related to change in muscle performance or physical function, but this is in
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conflict with other reports in the literature.5 Future studies should focus on teasing out
the relationship between IMAT and muscle function and its response to exercise.
Other investigators8 have indicated that muscle quality (peak torque/muscle
volume) may be a key component in muscle function. In this case study, strength
increased despite a decrease in muscle volume which would indicate an improvement in
muscle quality as defined by peak torque/muscle volume. It is possible that the
underlying contractile properties of the muscle were changed which could account for the
increase in peak torque independent of a change in muscle volume. It is also possible
that the improvement in muscle strength is due to a change in the nervous system rather
than a change in the muscle structure. We do not have measures that answer these
questions, but they should be investigated in future studies.
Of note, this subject’s HbA1c dropped by 0.5% from 6.9% to 6.4% indicating an
improvement in glucose control over the 12 weeks of exercise. Other exercise studies
have reported HbA1c reductions of 0.6-1.6% with combined aerobic and resistance
exercise programs of 8weeks-24months.23-27 In all of these studies, the exercise programs
were of higher intensity than the one we report here, and further study is needed to
determine if a higher intensity exercise program is safe and can result in larger drops in
HbA1c in people with DM+PN. We can only speculate that perhaps even with this
moderate intensity exercise program, the muscles improved insulin sensitivity which
could be responsible for the improvement in HbA1c. More research is needed to
determine if this speculation is accurate.
While this case study provides important information for clinicians, there are
limitations to be considered. First, this is a case study of a single subject and it is unclear
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whether these results are generalizable to the larger population of people with DM+PN.
This person did not have severe foot deformity or a history of plantar ulcer and more
studies are needed to determine the safety of this type of exercise for people with these
diabetic complications. We believe that our precautions of a detailed foot exam before
and after exercise are important components in people with DM+PN exercising safely.
We also used temperature measures from the plantar surface of the foot as a means of
identifying areas that might be at risk for skin breakdown.18 However, there were
multiple false positives (cases where the temperature difference was >4 degrees between
the right and left foot without other signs or symptoms indicating tissue damage). For this
subject, we concluded that the detailed visual foot examination before and after exercise
was adequate to prevent injury. Additional research is needed to investigate the
usefulness of temperature readings in populations at risk for skin injury.
This case report provides an example of a weightbearing exercise program that
was successfully implemented for a person with DM+PN. He was able to complete the
program without injury and increase six minute walk distance, increase plantarflexor
peak torque, and increase his average daily step count. More work is needed to
determine the appropriate intensity of exercise to elicit changes in muscle structure and to
determine the safety of high intensity resistance and/or aerobic exercise in people with
DM+PN.
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Table 1. Exercises performed during week 1 and week 12. Progression was determined
at each exercise session based on the subject’s subjective report of an exercise becoming
easy and his tolerance for increasing his repetitions on an exercise.
Week 1
Week 12
Toe crunches, 10 reps 2 times
Toe crunches, 35 reps 2 times
Single leg stand with one hand support, 30
Single leg stand with no hand support, 30
seconds 2 times
seconds 2 times
Step sideways and step backwards, 10 steps
Step over 5 cones, 3 times
each 2 times
2 leg heel stands (toes up), 10 reps 2 times
2 leg heel stands (toes up) 20 reps 2 times
Single leg toe raises (heels up) 40 reps 2
2 leg toe raises (heels up), 10 reps 2 times
times
Sit to stand, 5 reps 2 times
Sit to stand 20 reps 2 times
Step Ups with one hand support, 10 reps 2
Climb 2 flights of stairs, 2 times
times
24 min walk on treadmill, self-selected
14 min walk on treadmill, self-selected pace
pace
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Table 2. Outcome measures.
Measure
Pre Exercise Post Exercise
Six Minute Walk Distance (feet)
1200
1470
PPT Score
29
30
FAAM Score (%)
89
98
Self-Report FAAM Score (%)
98
100
Dorsiflexor Peak Torque (Nm) Right/Left
4.5/2.8
4.6/3.8
Plantarflexor Peak Torque (Nm) Right/Left
44.7/40.8
62.4/56.0
Average Daily Step Count
6176
8273
HbA1c (%)
6.9
6.4
IMAT volume (cm3)
48
56
Muscle volume (cm3)
426
390
Weight (lbs)
178
165
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Figure 1: Step Activity Monitor Data by Week.
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Chapter 6
Summary of Major Findings

104

Summary of Key Findings
The objectives of this research were to describe skeletal muscle structure in people
with diabetes and peripheral neuropathy, to determine whether neuropathic muscle
structure and composition is associated with movement impairments and functional
limitations, and to determine whether neuropathic muscle can be modulated by activity
level and/or an exercise intervention.
Chapter 2 asked the questions: does the presence of diabetes mellitus (DM) and
peripheral neuropathy (PN) have an additive affect on IMAT in the calf beyond the
presence of obesity? And how does IMAT impact function in a group with DM, a group
with DM+PN and a group with NoDMPN? Our results suggest that the presence of DM
and DM+PN do not have an additive affect on calf IMAT as there were no differences in
calf IMAT between the 3 groups. IMAT was associated with worse physical
performance, however, and both the DM and DM+PN group had lower measures of
physical performance in comparison to the NoDMPN group. In addition, it appears that
calf muscles may be affected by IMAT differently. Specifically, the gastrocnemius
muscle had the highest ratio of IMAT/Muscle Volume of any other calf muscle.
These results add to our knowledge of IMAT in that it continues to be related to
physical performance, but DM and PN do not seem to increase IMAT accumulation
independently of obesity. However, the group with DM and DM+PN had lower
measures of physical performance, indicating that the presence of pathology such as DM
and DM+PN impact physical performance beyond what is fully explained by IMAT in
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the calf. This is also the first study to report muscle specific differences in IMAT
accumulation, which will warrant future study.
Chapter 3 asked the question: how active are people with DM+PN and is activity
(average daily step count) related to calf IMAT in people with DM+PN? Our results
show that people with DM+PN are able to maintain a higher level of activity on average
than what we originally expected. Activity was inversely associated with IMAT, but was
not associated with measures of performance or glucose control. Interestingly, IMAT was
associated with measures of muscle performance and physical function, indicating that
activity level may be a modifiable factor with the potential to impact IMAT and possibly
impact physical function in people with DM+PN.
Chapters 4 and 5 asked the question: can neuropathic muscles adapt after an
exercise program and can people with DM+PN improve physical function after an
exercise program? Our results show that in response to a duration based walking
program, overall, people with DM+PN are able to increase 6 minute walk distance.
Changes in muscle strength as a group were variable, but some individuals were able to
increase average activity, increase muscle strength and improve physical performance.
Interestingly, these changes occurred without a consistent change in muscle volume or
IMAT.
In summary, our data suggests that IMAT is associated with physical
performance, but the presence of DM+PN are key factors that influence performance
overall. In addition, activity level is also related to IMAT, but more study is needed to
determine the exact exercise prescription that is safe and appropriate to cause changes in
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muscle volume and IMAT in people with DM+PN. It is possible to have improvements in
overall performance that are not reflected in changes in gross muscle morphology in the
calf muscles.
Limitations
There are several limitations to these studies; 1) small sample sizes, 2) potential
for a selection bias due to recruitment for an exercise study, 3) generalizability to those
with ulceration and foot deformity, 4) lack of activity measures for all participants, and
5) lack of histology measures. First, the sample sizes for these studies are relatively
small. It is possible that with larger sample sizes, we would have been able to better
characterize variables that contribute to IMAT. Secondly, the people with DM+PN who
participated in these studies were all interested in an ongoing study involving exercise for
people with DM+PN. It is possible that this led us to recruit the most active and highest
functioning people with DM+PN and we are not fully capturing a broad spectrum of the
whole population with DM+PN. Third, one of the requirements for participation in these
studies was a lack of foot deformity and we had very few participants with a history of
ulcer. These results should not be generalized to people who have these complications.
Fourth, we do not have activity measures for the groups with DM only or NoDMPN, so it
is possible that these groups are different from the DM+PN group in activity, which
could be a confounding variable in our results. Fifth, we do not have histology measures
or measures of changes that may be occurring on a smaller level in the muscle. We do not
know whether we would see group differences in histology between people with DM,
DM+PN and NoDMPN, or whether the exercise program was perhaps altering muscle

107

composition in a manner that we are not able to observe due to the gross MRI measures
that we are using.
Clinical Implications
Based on these results, people with DM+PN display lower levels of physical
function than their peers, although it is unclear whether IMAT is the key predictor of this
decline in physical function and whether or not interventions aimed at decreasing IMAT
will result in improved physical function. People with DM+PN are able to tolerate high
levels of physical activity without suffering from skin breakdown. Health care workers
should continue to educate people with DM+PN on the importance of increased physical
activity and the necessary precaution of a detailed foot examination daily to prevent skin
injury. While the 12 week duration-based intervention did not successfully change
muscle or adipose tissue morphology in the calf, the participants were successful in
increasing six minute walk distance. This speaks to the importance of specificity of
training—these participants were training using walking as the primary exercise and they
were indeed able to walk further.
Future Studies
Future studies are needed with larger sample sizes and with imaging data
collected on the entire lower extremity rather than just the calf or just the thigh to
determine whether IMAT accumulation is muscle specific throughout the lower
extremity. Our data suggest that the gastrocnemius is affected by IMAT accumulation
more so than other muscles and it is unknown whether other muscles in the lower
extremity are preferentially affected, but there is evidence in the literature that there are
higher amounts of IMAT in the foot muscles compared to more proximal muscle in the
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lower extremity in people with DM+PN. Future studies should attempt targeted
interventions for the gastrocnemius muscle in an effort to determine if IMAT can be
changed. Also, studies with more longitudinal data and longer follow ups that what is
presented here are needed. The natural history of the disease of DM and DM+PN is one
of decline in strength and function, so a longer follow up would provide more insight on
the effects of higher levels of activity or of an intervention.
The ideal magnitude, duration and type of intervention to cause safe changes in
the morphology of neuropathic muscle remain unclear. The American Diabetes
Association and the American College of Sports Medicine have only recently changed
their guidelines to indicate that people with DM+PN may participate in moderate
intensity exercise. Future studies should examine a higher intensity exercise program—
both aerobic and resistance based—to determine the impact this has on muscle structure
and physical performance and the safety of high intensity exercise in people with
DM+PN. Based on our data, it is unclear whether neuropathic muscle has the potential to
adapt muscle morphology in response to exercise, but a higher intensity strengthening
program would provide clinicians with more useful information in this regard. In
addition, measures of nerve function such as nerve conduction velocity testing would
provide information about adaptation in this population. It is possible that the exercise
program altered the nervous system in some way and that accounts for the changes in 6
minute walk distance and would explain why we did not see changes in muscle
morphology.
Overall, our results suggest that people with DM+PN have lower levels of
physical performance than their peers and increased IMAT is associated with poor
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physical performance and may be muscle specific. Increased activity levels are
associated with decreased IMAT volume, and people with DM+PN are able to safely
increase their walking distance following an exercise intervention, but we did not see a
change in muscle composition. Additional research is needed to determine the specific
roles of IMAT in skeletal muscle and function.
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Appendix A
Magnetic Resonance Spectroscopy
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Originally, I proposed to use magnetic resonance spectroscopy to investigate
intramyocellular and extramyocellular lipid content in the calf muscles of people with
diabetes and peripheral neuropathy. I was able to collect and analyze these data,
however, because of difficulty in finding appropriate voxel placement in muscles with
high amounts of visible adipose tissue and difficulty in interpreting the results from these
scans, the information has been included in this appendix rather than in a primary chapter
of the dissertation.
Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that
allows investigators to examine metabolites within the muscle. 1H-MRS makes it
possible to observe intramyocellular lipids (IMCL) and extramyocellular lipids (EMCL)
within the muscle. Intramyocellular lipids are stored in the form of lipid droplets in the
cytoplasm in close contact with the mitochondria in the muscle cell (1). The ability to
observe IMCL via 1H-MRS gained popularity when it became clear that IMCL can be
recruited for use during strenuous exercise (2). The observation of increased IMCL in
diabetic and insulin-resistant individuals supported the hypothesis that increased IMCL
within the muscle could be a part of skeletal muscle insulin resistance (3-6).
Recently, measures of IMCL have been used to measure outcomes in a cohort of
elderly obese individuals participating in either a diet only intervention or a combined
diet and exercise intervention (7). The preliminary results of this study show an increase
in IMCL in the soleus muscle in the diet and exercise group and no change in the IMCL
content of the medial gastrocnemius. It is possible that increased IMCL in the soleus
muscle may have been a positive adaptation in the diet and exercise group as the result of
endurance activity such as the IMCL noted in highly trained athletes (8). Any
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information on how neuropathic muscle responds or fails to respond to an intervention
will provide health care providers with important information about how diabetic and
neuropathic muscle adapts.
The goal was to determine if there was a difference in IMCL and EMCL in the
gastrocnemius and soleus muscles in a group with diabetes (DM), a group with diabetes
and peripheral neuropathy (DM+PN) and an age and BMI matched group without
diabetes and peripheral neuropathy (NoDMPN). A secondary goal was to determine if
IMCL and EMCL in the gastrocnemius and soleus muscle changes in response to an
exercise program for people with DM+PN.
Methods
IMCL and EMCL values were quantified using proton spectroscopy on the right
calf of each participant with a 3.0-T superconducting MRI instrument using a point
resolved spectroscopy (PRESS) single-voxel technique (9). The participants were
positioned in supine with an extremity coil over the calf. Spectra were collected at echo
times of 30 and 60 ms to approximate and correct for the T2 decay of the signals (9). An
initial scout scan was performed in order to localize the calf musculature. A 1cm3 voxel
region of interest was chosen, avoiding vessels and apparent adipose depots in the medial
gastrocnemius muscle (2 voxels) and the soleus muscle (3 voxels). Fig 1. The data was
processed and analyzed using jMRUI 3.0 with an AMARES fitting algorithm and using
prior knowledge of the water and IMCL frequencies (10-13). Fig 2. An average of the
IMCL from the voxels in each muscle was used for analysis and are reported as a
percentage of the water peak in arbitrary units.
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A one-way ANOVA was used to determine group differences (DM vs. DM+PN
vs. NoDMPN) and a repeated measures ANOVA was used to determine differences in
groupxtime. A power analysis was conducted based on the means and standard deviations
listed in Table 2 using GPower 3.0.10 software to determine the sample size necessary to
detect differences using repeated measures ANOVA and the results of this analysis are
listed in Table 2.
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Results
Table 1: Group differences in IMCL and EMCL. Values are mean (SD). P-values
are from one way ANOVA.
DM
DM+PN
NoDMPN
P-Values
Soleus
2.8(1.9)
3.1(2.5)
3.7(5.6)
0.83
IMCL(AU)
N=9
N=18
N=8
Soleus
3.1 (1.8)
5.6 (5.4)
5.6 (6.5)
0.46
EMCL(AU)
N=9
N=18
N=8
Gastrocnemius
2.1(1.7)
3.5(4.7)
1.6(1.4)
0.42
IMCL(AU)
N=8
N=10
N=8
Gastrocnemius
4.5 (3.4)
11.4 (19.6)
5.7(5.3)
0.48
EMCL(AU)
N=8
N=10
N=8
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Table 2: Pre and post exercise IMCL and EMCL values. Values are mean (SD).
Pre

Post

SOL IMCL
EX Group N=9
4.9 (7.2)
CON Group N=7
3.9 (3.7)
SOL EMCL
EX Group N=9
6.3 (6.7)
CON Group N=8
7.5 (7.5)
GAST IMCL
EX Group N=6
6.6 (8.1)
CON Group N=3
4.2 (3.2)
GAST EMCL
EX Group N=6
13.2 (17.5)
CON Group N=3
2.3 (3.2)
No groupxtime differences (P>0.05)

Power Analysis
1962

4.9 (5.0)
5.9 (8.1)
830
7.3 (5.9)
6.4 (7.2)
150
2.8 (4.4)
3.0 (3.6)
26
6.5 (8.1)
3.8 (3.2)

Power Analysis: total number of subjects needed to determine group differences using a
repeated measures ANOVA.
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Discussion
There were no differences in IMCL and EMCL values between the DM, DM+PN
and NoDMPN groups (Table 1). There was also no change in IMCL and EMCL in the
EX group or the CON group from pre to post exercise testing (Table 2). There are
several limitations to be considered. First, the IMCL and EMCL values in the
gastrocnemius and soleus muscles are highly variable—notice that the standard
deviations often exceed the mean value. This high variance makes detecting group
differences or changes over time difficult, particularly in a small sample. Also, as noted
in the methods, when choosing a voxel, the goal is to avoid vessels and frank adipose
tissue. Appropriate voxel placement becomes impossible in cases where the
gastrocnemius or soleus has large amounts of intermuscular adipose tissue (Fig 3) and
makes the results either invalid or difficult to interpret. The N is variable in the groups
because of the invalid data. The average ratio of IMAT/Muscle volume in the
gastrocnemius muscle of the subjects with invalid data (N=19) across the DM, DM+PN
and NoDMPN groups was 0.43 with a standard deviation of 0.53 and a range of 0.11 to
1.848. More data is needed to determine a true threshold of IMAT infiltration that makes
MRS data difficult to interpret due to the difficulty in voxel placement. It is unclear
whether the results would be improved with the use of larger magnets or smaller voxel,
but this should be considered for future studies. While MRS provides data regarding
IMCL and EMCL in individual muscles and allows investigators to measure fat within a
muscle cell, it seems that this technique is not feasible as a measure in populations with
large amounts of IMAT such as people who are obese, and have DM and PN due to
difficulty in voxel placement as well as interpretation of large fat peaks using current
analysis methods.
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Figure 1. Example of voxel placement in the medial gastrocnemius muscle of a subject
with low intermuscular adipose tissue.
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Figure 2. Example of a spectrum collected using MRS protocol. Notice the large water
peak and the much smaller IMCL and EMCL peaks to the right of the water peak.
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Figure 3. Examples of subjects with large amounts of IMAT in the gastrocnemius and
soleus muscles making voxel placement in areas without adipose tissue impossible.
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Appendix B
DXA vs. MRI for IMAT analysis
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There are multiple ways to determine body composition including amount of fat
and muscle in a particular area of the body. Dual-energy x-ray absorptiometry (DXA)
can be used to distinguish soft tissue from bone and to distinguish fat from lean (muscle)
tissue. DXA is reliable and valid1 and allows the user to look at regional areas of fat and
lean muscle, such as the leg. DXA has the benefit of being non-invasive, as well as a very
fast imaging tool (6 minutes for a whole body scan), but has the drawback of using
radiation and has limited resolution.
MRI can also be used to determine fat and lean tissue in a region of interest due to
inherent tissue contrast because of different amounts of water in different tissues. MRI is
also a non-invasive imaging tool, but the MR scans typically will take longer and will
image a smaller area of interest. For example, the MR protocol that is used to scan the
calf takes 4.5 minutes to scan 21cm of the calf compared to 6 minutes for a whole body
DXA scan. Unlike DXA, MRI does not use radiation and has superior resolution to look
at body structures, however the cost for MRI is significantly higher than DXA.
One might be interested in trying to parse out the fat between and within an
individual muscle compartment (Intermuscular adipose tissue or IMAT), but it is unclear
whether or not DXA would provide this capability. It is also unclear whether the fat
reported in DXA measures correspond entirely with subcutaneous fat or if it is able to
capture IMAT as well.
Using the data set of the 45 participants from chapter 2—11 people with type 2
diabetes [5men/6 women; aged 56(9); BMI 35.5(6.4)], 24 people with diabetes and
peripheral neuropathy [15 men/9 women; aged 64(13); BMI 32.6(6.3)], and 10 people
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without diabetes and without peripheral neuropathy [4 men/6 women; aged 64(9); BMI
32.9(4.6)], I compared DXA measures and MRI measures using Pearson correlations.
There was a high correlation between calf total fat in cm3 via MRI (subcutaneous
fat and IMAT) and the leg fat in grams measured via DXA (r=0.78) (Figure 1). There
was a low correlation between calf IMAT in cm3 measured via MRI and the leg fat in
grams measured via DXA (r=0.20) (Figure 2). There was also a significant correlation
between BMI and body fat percentage as measured using DXA (r=0.60) (Figure 3), but
there was a fair amount of variability around the trend line.
Based on this analysis, it is necessary to use MRI to measure IMAT, but DXA
provides an alternate tool for measures of whole body and regional body composition. In
addition, DXA may provide another way to characterize obesity or regional adiposity that
is more specific than BMI and may be more powerful when looking at specific regions of
interest between groups.
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Figure 1.

R=0.78
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Figure 2.

R=0.20
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Figure 3.

R=0.60
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Appendix C
Exercise Intervention Daily Checklist, Stretching and Weight-Bearing Exercises
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Exercise Study for People with Diabetes and Peripheral Neuropathy
Program in Physical Therapy, Washington University School of Medicine
Daily Stat and Check Sheet -To be completed before and after every intervention session
Date:___________________
Subject ID:___________________
DOB:_____________________
Weight:___________________
Participant comments before exercise:_______________________________________
Screening: Footwear: Adequate [] Not adequate [] (See footwear checklist for guidelines)
Digital Photograph
Before
Yes []
After
Yes []

Pulse
_____
_____

Blood Pressure
_____/_______
_____/_______

Glucose Level
_____
_____

Plantar Skin Temperature
Med Lateral
Before
Great Toe Met 1 Met 3 Met 5 Midft Midft Heel
Left
_______ _____ _____ _____ _____ _____ _____
Right
_______ _____ _____ _____ _____ _____ _____
Difference _______ _____ _____ _____ _____ _____ _____
***(4 degree F (2.2 degree C) difference side to side indicates participant should monitor
skin carefully and reduce activity as per study coordinator)***
After
Left
_______ _____ _____ _____ _____ _____ _____
Right
_______ _____ _____ _____ _____ _____ _____
Difference _______ _____ _____ _____ _____ _____ _____
***(4 degree F (2.2 degree C) difference side to side indicates participant should monitor
skin carefully and reduce activity as per study coordinator)***
Barefoot Visual Inspection Describe any blisters, redness, cracking, rash, lesion, nail color,
and describe any area with a temperature change of 4 degrees F or greater--Complete wound
documentation form if any new lesion exists.
Before __________________________________________________________
After ____________________________________________________________
Intervention Target heart rate range (220-age): _______________
HR monitored during exercise [ ] ________
20 minutes of flexibility, balance, and strengthening exercises
Provide group and level specific instructions WB or NWB Level_____.
Blood Glucose Monitored: Pre exercise:________ Post exercise______.
Minutes of walking / stationary bike: Target _______ Actual_______
Step count during intervention: Pedometer _______ SAM______
RPM (bike)______
Exercise Precautions for all participants: Exercise postponed because
_____1) Blood glucose >300 mg/dl,
_____2) Resting systolic BP of >200 mm Hg,
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_____3) Resting diastolic BP of >110 mm hg.
_____4) Blood glucose is <80-100mg/dl (ACSM guidelines) carbohydrates were ingested.
_____5) Target heart rate is intended to be 40-60% of age-predicted maximum, and
activity will be adjusted to stay within those limits using a heart rate monitor.
Participant comments, complaints, or observations from Physical Therapist or study coordinator.
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Toe Stretch
*Sitting, cross right foot up onto thigh
*Grasp toes of right foot with your hand and curl the toes down
*Then point ankle and foot down (in the direction you push on the gas pedal)
*Hold 30 seconds
*Repeat with left leg
*Repeat entire sequence 2 times
Hamstring Stretch

133

*Lie on your back
*Clasp your right thigh and pull it toward you
*Extend your knee, keeping your back and thigh still, until you feel a gentle stretch in the back of your right thigh
*Hold stretch 30 seconds, return to start position
*Repeat with left leg
*Repeat entire sequence 2 times

Knee Flexion, Face lying

*Lie face down with your legs straight and relatively close together
*Bend your right knee
*Don’t let your back move as you bend your knee
*Hold for 30 seconds then return your leg to starting position
*Repeat with left leg
*Repeat entire sequence 2 times

Hands and Knees Rocking Back

*Get on your hands and knees
*Rock back toward your heels, keeping your back straight
*Return to start position
*Repeat 2 times

Standing Calf Stretch
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*Stand facing the wall
*Lean to the wall and place right foot forward
*Make sure your foot is facing straight forward, not turned out to the side
*Keeping your back heel on the ground, lean forward till gentle stretch is felt in your calf
*Hold stretch 30 seconds, return to start position
*Repeat with left leg
*Repeat entire sequence 2 times
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Level 1
1. Toe Crunches, on mat
*10 reps

Level 2
1. Toe Crunches, on mat
*15 reps

Level 3
1. Toe Crunches, on mat
*20 reps

Level 4
1. Toe Crunches, on mat
*25 reps

Level 5
1. Toe Crunches, on mat
*30 reps

Level 6
1. Toe Crunches, on mat
*35 reps

2. One-leg stand with
bilateral hand support
*30 seconds, 2 times

2. One-leg stand with
one hand support
*30 seconds, 2 times

2. One-leg stand no
hand support
*30 seconds, 2 times

2. Stand with 2 feet on
balance disc, bilateral
hand support
*30 seconds, 2 times

2. Stand with 2 feet on
balance disc, no hand
support
*30 seconds, 2 times

2. One-leg stand on
balance disc, with
bilateral hand support
*30 seconds, 2 times

3. Step sideways and
then step backwards
with one hand support
*10 steps (across
room), 2 times each

3. Step sideways and
then step backwards
with no hand support
*10 steps (across
room), 2 times each

3. Step sideways on
exercise mat, and then
backwards on exercise
mat with one hand
support *10 steps,
(across room), 2 times
each

3. Step sideways on
exercise mat, and then
backwards on exercise
mat with one hand
support *10 steps,
(across room), 2 times
each

3. Step over objects, no
hand support
*5 objects, 3 times
(Ok to alternate with
level 5 content but
increase to 3 times each)

3. Step over objects, no
hand support
*10 objects, 3 times
(Ok to alternate with
level 5 content but
increase to 3-4 times
each)

4. 2 leg heel stand (toes
up) , back against wall
*5 reps

4. 2 leg heel stand (toes
up), back against wall
*10 reps

4. 2 leg heel stand (toes
up), back against wall
*15 reps

4. 2 leg heel stand
(toes up), back against
wall
*20 reps

4. Single Leg heel stand
(toes up), back against
wall
*10 reps

4. Single Leg Heel Stand
(toes up), back against
wall
*15 reps

5. 2 leg toe raises (heels
up)
*5 reps

5. 2 leg toe raises
*10 reps

5. 2 leg toe raises
*15 reps

5. 2 leg toe raises
*20 reps

5. Single leg toe raises
*5 reps each side

5. Single leg toe raises
*10 reps each side

6. Sit to stand
*3 reps

6. Sit to stand
*5 reps

6. Sit to stand
*7 reps

6. Sit to stand
*10 reps

6. Sit to stand
* 12 reps

6. Sit to stand
*15 reps

7. step ups, with two
hand support
*10 reps

7. step ups, with one
hand support
*10 reps

7. step ups, with no
hand support
*10 reps

7. stair climbing, with
one hand support
*up and down 5 stairs

7. stair climbing, with
one hand support
*up and down 1 flight

7. stair climbing, hand
support as needed
*up and down up to 4
flights

